1
|
Oropeza E, Seker S, Carrel S, Mazumder A, Lozano D, Jimenez A, VandenHeuvel SN, Noltensmeyer DA, Punturi NB, Lei JT, Lim B, Waltz SE, Raghavan SA, Bainbridge MN, Haricharan S. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Sci Adv 2023; 9:eadf2860. [PMID: 37390209 PMCID: PMC10313178 DOI: 10.1126/sciadv.adf2860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 05/26/2023] [Indexed: 07/02/2023]
Abstract
Cell cycle dysregulation is prerequisite for cancer formation. However, it is unknown whether the mode of dysregulation affects disease characteristics. Here, we conduct comprehensive analyses of cell cycle checkpoint dysregulation using patient data and experimental investigations. We find that ATM mutation predisposes the diagnosis of primary estrogen receptor (ER)+/human epidermal growth factor (HER)2- cancer in older women. Conversely, CHK2 dysregulation induces formation of metastatic, premenopausal ER+/HER2- breast cancer (P = 0.001) that is treatment-resistant (HR = 6.15, P = 0.01). Lastly, while mutations in ATR alone are rare, ATR/TP53 co-mutation is 12-fold enriched over expected in ER+/HER2- disease (P = 0.002) and associates with metastatic progression (HR = 2.01, P = 0.006). Concordantly, ATR dysregulation induces metastatic phenotypes in TP53 mutant, not wild-type, cells. Overall, we identify mode of cell cycle dysregulation as a distinct event that determines subtype, metastatic potential, and treatment responsiveness, providing rationale for reconsidering diagnostic classification through the lens of the mode of cell cycle dysregulation..
Collapse
Affiliation(s)
- Elena Oropeza
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Sinem Seker
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Sabrina Carrel
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Aloran Mazumder
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Daniel Lozano
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Athena Jimenez
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | | | | | - Nindo B. Punturi
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Jonathan T. Lei
- Lester and Sue Smith Breast Cancer Center, Baylor College of Medicine, Houston, TX, USA
| | - Bora Lim
- Lester and Sue Smith Breast Cancer Center, Baylor College of Medicine, Houston, TX, USA
- Department of Oncology/Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Susan E. Waltz
- Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA
- Research Service, Cincinnati Veteran's Affairs Medical Center, 3200 Vine St., Cincinnati, OH, USA
| | | | | | - Svasti Haricharan
- Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| |
Collapse
|
2
|
Richardson A, Darst B, Wojcik G, Wagle N, Haricharan S. Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations. Clin Cancer Res 2023; 29:1194-1199. [PMID: 36638200 PMCID: PMC10073283 DOI: 10.1158/1078-0432.ccr-22-3182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 12/08/2022] [Accepted: 01/11/2023] [Indexed: 01/15/2023]
Abstract
Despite much vaunted progress in cancer therapeutics and diagnostics, outcomes for many groups of non-White patients with cancer remain worse than those for their White compatriots. One reason for this is the lack of inclusion and representation of non-White patients in clinical trials, preclinical datasets, and among researchers, a shortfall that is gaining wide recognition within the cancer research community and the lay public. Several reviews and editorials have commented on the negative impacts of the status quo on progress in cancer research toward medical breakthroughs that help all communities and not just White patients with cancer. In this perspective, we describe the existence of research silos focused either on the impact of socioeconomic factors proceeding from systemic racism on cancer outcomes, or on genetic ancestry as it affects the molecular biology of cancer developing in specific patient populations. While both these research areas are critical for progress toward precision medicine equity, breaking down these silos will help us gain an integrated understanding of how race and racism impact cancer development, progression, and patient outcomes. Bringing this comprehensive approach to cancer disparities research will undoubtedly improve our overall understanding of how stress and environmental factors affect the molecular biology of cancer, which will lead to the development of new diagnostics and therapeutics that are applicable across cancer patient demographics.
Collapse
Affiliation(s)
| | - Burcu Darst
- Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA
| | - Genevieve Wojcik
- Dept of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
| | - Nikhil Wagle
- Dept of Medicine, Harvard Medical School, Boston, MA
- Dana-Farber Cancer Institute, Boston, MA
| | - Svasti Haricharan
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| |
Collapse
|
3
|
Seker S, Oropeza E, Carrel S, Mazumder A, Punturi N, Lei J, Anurag M, Lim B, Bainbridge M, Haricharan S. Abstract P3-10-02: Cell cycle dysregulation in breast cancer: why the details matter. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p3-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Cell cycle dysregulation is a prerequisite for cancer formation. However, whether the type of cell cycle dysregulation event a cell incurs during transformation to malignancy influences the type of cancer that evolves or clinical outcome is unknown. In a comprehensive analysis of cell cycle dysregulation in breast cancer patient tumors, we associate mutations in each of four cell cycle checkpoint kinase genes, ATM, CHEK2, ATR and CHEK1, with known tumor characteristics and clinical outcome, and test these associations experimentally using transgenic mice, patient-derived xenografts and breast cancer cell line model systems. Results of this work demonstrate that dysregulation of specific cell cycle checkpoint kinases differently impacts the type of breast cancer that evolves in patients and in experimental model systems, and influences treatment responsiveness and disease progression. For instance, CHEK2 mutations associate preferentially with the incidence of metastatic, premenopausal estrogen receptor (ER)+/HER2- breast cancer in patient data (p=0.001) that is resistant to standard frontline therapy (HR=6.15, p=0.01). These associations appear causal when tested in an immune-competent genetically-engineered mouse model of Chk2 loss, in patient-derived xenograft, and in cell line experiments. On the other hand, ATR mutation by itself is not frequent in ER+/HER2- breast cancer, but co-incident mutation of ATR and TP53 is 2-fold enriched (p=0.002) and associates with metastatic progression (HR=2.01, p=0.007). Concordantly, ATR dysregulation induces metastatic phenotypes in ER+/HER- TP53 mutant, but not in TP53 wildtype, cell lines. Together, these results systematize the impact of individual cell cycle checkpoint kinases on the evolution of cancer subtypes, and on disease progression. Statement of Significance These findings reframe the paradigm of breast cancer classification through the lens of early cell cycle dysregulation events by demonstrating that cell cycle decisions during malignant transformation can direct the type of breast cancer that evolves, how it will respond to treatment, and whether it will metastasize. This work provides rationale for streamlined testing of checkpoint kinase dysregulation to improve precision diagnostics for cancer patients.
Citation Format: Sinem Seker, Elena Oropeza, Sabrina Carrel, Aloran Mazumder, Nindo Punturi, Jonathan Lei, Meenakshi Anurag, Bora Lim, Matthew Bainbridge, Svasti Haricharan. Cell cycle dysregulation in breast cancer: why the details matter [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-10-02.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Bora Lim
- 8Baylor College of Medicine, Houston, TX
| | | | | |
Collapse
|
4
|
Lovejoy LA, Shriver CD, Haricharan S, Ellsworth RE. Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer. Int J Environ Res Public Health 2023; 20:2903. [PMID: 36833598 PMCID: PMC9956998 DOI: 10.3390/ijerph20042903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/31/2023] [Accepted: 02/02/2023] [Indexed: 06/18/2023]
Abstract
Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2-) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.
Collapse
Affiliation(s)
- Leann A. Lovejoy
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA
| | - Craig D. Shriver
- Murtha Cancer Center/Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
- Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20889, USA
| | - Svasti Haricharan
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
| | - Rachel E. Ellsworth
- Murtha Cancer Center/Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
| |
Collapse
|
5
|
Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, Burglen L, Cope H, Crawford A, Derksen A, Dure L, Gantz E, Koch-Hogrebe M, Hurst ACE, Mahida S, Marshall P, Micalizzi A, Novelli A, Peng H, Rodriguez D, Robbins SL, Rutledge SL, Scalise R, Schließke S, Shashi V, Srivastava S, Thiffault I, Topol S, Qebibo L, Wieczorek D, Cravatt B, Haricharan S, Torkamani A, Friedman J. Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain 2022; 145:3383-3390. [PMID: 35737950 PMCID: PMC9586540 DOI: 10.1093/brain/awac223] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 05/30/2022] [Indexed: 11/12/2022] Open
Abstract
The endocannabinoid system is a highly conserved and ubiquitous signalling pathway with broad-ranging effects. Despite critical pathway functions, gene variants have not previously been conclusively linked to human disease. We identified nine children from eight families with heterozygous, de novo truncating variants in the last exon of DAGLA with a neuro-ocular phenotype characterized by developmental delay, ataxia and complex oculomotor abnormality. All children displayed paroxysms of nystagmus or eye deviation accompanied by compensatory head posture and worsened incoordination most frequently after waking. RNA sequencing showed clear expression of the truncated transcript and no differences were found between mutant and wild-type DAGLA activity. Immunofluorescence staining of patient-derived fibroblasts and HEK cells expressing the mutant protein showed distinct perinuclear aggregation not detected in control samples. This report establishes truncating variants in the last DAGLA exon as the cause of a unique paediatric syndrome. Because enzymatic activity was preserved, the observed mislocalization of the truncated protein may account for the observed phenotype. Potential mechanisms include DAGLA haploinsufficiency at the plasma membrane or dominant negative effect. To our knowledge, this is the first report directly linking an endocannabinoid system component with human genetic disease and sets the stage for potential future therapeutic avenues.
Collapse
Affiliation(s)
- Matthew N Bainbridge
- Rady Children's Institute for Genomic Medicine (RCIGM), San Diego, CA 92123, USA
| | - Aloran Mazumder
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
| | - Daisuke Ogasawara
- The Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Rami Abou Jamra
- Institute of Human Genetics, University Medical Center Leipzig, Leipzig 04103, Germany
| | - Geneviève Bernard
- Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.,Department of Pediatrics and Human Genetics, McGill University, Montreal, Canada.,Department of Human Genetics, McGill University, Montreal, Canada.,Department Specialized Medicine, Division of Medical Genetics, McGill University Health Center, Montreal, Canada.,Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada
| | - Enrico Bertini
- Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences 'Bambino Gesu' Children's Research Hospital, IRCCS, Rome, Italy
| | - Lydie Burglen
- Centre de Référence Malformations et Maladies Congénitales du Cervelet, Département de génétique, AP-HP Sorbonne Université, Hôpital Trousseau, Paris, France.,Developmental Brain Disorders Laboratory, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Heidi Cope
- Department of Pediatrics, Division Medical Genetics Durham, Duke University Medical Center, North Carolina, USA
| | | | - Alexa Derksen
- Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.,Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada
| | - Leon Dure
- Division of Pediatric Neurology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Emily Gantz
- Division of Pediatric Neurology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | | | - Anna C E Hurst
- Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Sonal Mahida
- Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Paige Marshall
- Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Alessia Micalizzi
- Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy
| | - Antonio Novelli
- Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy
| | - Hongfan Peng
- The Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Diana Rodriguez
- Sorbonne Université, INSERM UMR 1141, AP-HP.SU, Centre de Référence Maladies Rares Malformations et Maladies Congénitales du Cervelet & Service de Neuropédiatrie, Hôpital Trousseau, Paris, France
| | - Shira L Robbins
- Ratner Children's Eye Center at the Shiley Eye Institute; Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, CA 92093, USA
| | - S Lane Rutledge
- Division of Pediatric Neurology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.,Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Roberta Scalise
- Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, Pisa, Italy.,Tuscan PhD Program of Neuroscience, University of Florence, Pisa and Siena, Florence, Italy
| | - Sophia Schließke
- Institute of Human Genetics, University Medical Center Leipzig, Leipzig 04103, Germany
| | - Vandana Shashi
- Department of Pediatrics, Division Medical Genetics Durham, Duke University Medical Center, North Carolina, USA
| | | | - Isabella Thiffault
- Genomic Medicine Center, Children's Mercy Hospital, Kansas City, Missouri, USA.,Faculty of Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA.,Department of Pathology, Children's Mercy Hospital, Kansas City, Missouri, USA
| | - Sarah Topol
- The Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Leila Qebibo
- Centre de Référence Malformations et Maladies Congénitales du Cervelet, Département de génétique, AP-HP Sorbonne Université, Hôpital Trousseau, Paris, France
| | - Dagmar Wieczorek
- Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, 40225, Düsseldorf, Germany
| | - Benjamin Cravatt
- The Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Svasti Haricharan
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
| | - Ali Torkamani
- The Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Jennifer Friedman
- Rady Children's Institute for Genomic Medicine (RCIGM), San Diego, CA 92123, USA.,Division of Neurology, Rady Children's Hospital San Diego, CA 92123, USA.,Department of Neurosciences, University of California La Jolla, CA 92037, USA.,Department of Pediatrics, University of California La Jolla, CA 92037, USA
| |
Collapse
|
6
|
VandenHeuvel SN, Farris HA, Noltensmeyer DA, Roy S, Donehoo DA, Kopetz S, Haricharan S, Walsh AJ, Raghavan S. Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models. Soft Matter 2022; 18:5791-5806. [PMID: 35894795 DOI: 10.1039/d1sm01796a] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Metastatic cancers are chemoresistant, involving complex interplay between disseminated cancer cell aggregates and the distant organ microenvironment (extracellular matrix and stromal cells). Conventional metastasis surrogates (scratch/wound healing, Transwell migration assays) lack 3D architecture and ECM presence. Metastasis studies can therefore significantly benefit from biomimetic 3D in vitro models recapitulating the complex cascade of distant organ invasion and colonization by collective clusters of cells. We aimed to engineer reproducible and quantifiable 3D models of highly therapy-resistant cancer processes: (i) colorectal cancer liver metastasis; and (ii) breast cancer lung metastasis. Metastatic seeds are engineered using 3D tumor spheroids to recapitulate the 3D aggregation of cancer cells both in the tumor and in circulation throughout the metastatic cascade of many cancers. Metastatic soil was engineered by decellularizing porcine livers and lungs to generate biomatrix scaffolds, followed by extensive materials characterization. HCT116 colorectal and MDA-MB-231 breast cancer spheroids were generated on hanging drop arrays to initiate clustered metastatic seeding into liver and lung biomatrix scaffolds, respectively. Between days 3-7, biomatrix cellular colonization was apparent with increased metabolic activity and the presence of cellular nests evaluated via multiphoton microscopy. HCT116 and MDA-MB-231 cells colonized liver and lung biomatrices, and at least 15% of the cells invaded more than 20 μm from the surface. Engineered metastases also expressed increased signatures of genes associated with the metastatic epithelial to mesenchymal transition (EMT). Importantly, inhibition of matrix metalloproteinase-9 inhibited metastatic invasion into the biomatrix. Furthermore, metastatic nests were significantly more chemoresistant (>3 times) to the anti-cancer drug oxaliplatin, compared to 3D spheroids. Together, our data indicated that HCT116 and MDA-MB-231 spheroids invade, colonize, and proliferate in livers and lungs establishing metastatic nests in 3D settings in vitro. The metastatic nature of these cells was confirmed with functional readouts regarding EMT and chemoresistance. Modeling the dynamic metastatic cascade in vitro has potential to identify therapeutic targets to treat or prevent metastatic progression in chemoresistant metastatic cancers.
Collapse
Affiliation(s)
| | - Heather A Farris
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Dillon A Noltensmeyer
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Sanjana Roy
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Del A Donehoo
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Scott Kopetz
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Svasti Haricharan
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Alex J Walsh
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
| | - Shreya Raghavan
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| |
Collapse
|
7
|
Mazumder A, Jimenez A, Ellsworth RE, George S, Freedland SJ, Bainbridge MN, Haricharan S. Abstract P3-14-03: The DNA damage repair landscape in Black women with breast cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p3-14-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Black women have 42% higher mortality rate from estrogen receptor positive (ER+) breast cancer than white women. Molecular mechanisms underlying worse outcome in black women are understudied. Recently, downregulation of specific DNA damage repair (DDR) genes was shown to causally induce resistance to standard care endocrine therapy by dysregulating cell cycle regulation, and to associate with poor outcome in white women with ER+ breast cancer. However, frequency and patterns of DDR dysregulation in Black women with ER+ breast cancer and impact on survival outcomes remains untested. By assessing RNA expression of 104 DDR genes across three tumor, and two normal breast, datasets, here, we map for the first time, global patterns of DDR gene expression regulation specific to Black women, both in tumors and in the normal breast. We identify a specific subset of 8 candidate DDR genes that are dysregulated at the RNA level in tumors from Black women. Of note, a novel DDR regulation signature where genes from the homologous recombination pathway are upregulated and genes from SSBR pathways (mainly base excision repair) are coincidently downregulated is almost uniquely detectable in tumors from Black women (8% incidence relative to 1% in tumors from white women, p=0.01). Moreover, this coincident DDR signature associates with dysregulated cell cycle gene expression (p<0.001). In accordance, patients whose tumors demonstrate this coincident DDR signature also have significantly worse survival outcomes across datasets (hazard ratio of 9.5, p<0.001). Overall, these results constitute the first systematic analysis of differences in DDR gene expression regulation between Black and white women and identify a specific DDR signature associated with poor outcome in tumors from Black women. These results provide new grounds for refining biomarker profiles and improving precision medicine for underserved populations.
Citation Format: Aloran Mazumder, Athena Jimenez, Rachel E Ellsworth, Sophia George, Stephen J Freedland, Matthew N Bainbridge, Svasti Haricharan. The DNA damage repair landscape in Black women with breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-14-03.
Collapse
Affiliation(s)
| | - Athena Jimenez
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Rachel E Ellsworth
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD
| | | | | | | | | |
Collapse
|
8
|
Mazumder A, Jimenez A, Ellsworth RE, Freedland SJ, George S, Bainbridge MN, Haricharan S. The DNA damage repair landscape in Black women with breast cancer. Ther Adv Med Oncol 2022; 14:17588359221075458. [PMID: 35154416 PMCID: PMC8829704 DOI: 10.1177/17588359221075458] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 01/06/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Estrogen receptor positive (ER+) breast cancer is one of the most commonly diagnosed malignancies in women irrespective of their race or ethnicity. While Black women with ER+ breast cancer are 42% more likely to die of their disease than White women, molecular mechanisms underlying this disparate outcome are understudied. Recent studies identify DNA damage repair (DDR) genes as a new class of endocrine therapy resistance driver that contributes to poor survival among ER+ breast cancer patients. Here, we systematically analyze DDR regulation in the tumors and normal breast of Black women and its impact on survival outcome. METHOD Mutation and up/downregulation of 104 DDR genes in breast tumor and normal samples from Black patients relative to White counterparts was assessed. For DDR genes that were differently regulated in the tumor samples from Black women in multiple datasets associations with survival outcome were tested. RESULTS Overall, Black patient tumors upregulate or downregulate RNA levels of a wide array of single strand break repair (SSBR) genes relative to their white counterparts and uniformly upregulate double strand break repair (DSBR) genes. This DSBR upregulation was also detectable in samples of normal breast tissue from Black women. Eight candidate DDR genes were reproducibly differently regulated in tumors from Black women and associated with poor survival. A unique DDR signature comprised of simultaneous upregulation of homologous recombination gene expression and downregulation of SSBR genes was enriched in Black patients. This signature associated with cell cycle dysregulation (p < 0.001), a hallmark of endocrine therapy resistance, and concordantly, with significantly worse survival outcomes in all datasets analyzed (hazard ratio of 9.5, p < 0.001). CONCLUSION These results constitute the first systematic analysis of DDR regulation in Black women and provide strong rationale for refining biomarker profiles to ensure precision medicine for underserved populations.
Collapse
Affiliation(s)
- Aloran Mazumder
- Aging, Cancer and Immuno-oncology Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Athena Jimenez
- Aging, Cancer and Immuno-oncology Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Rachel E. Ellsworth
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| | - Stephen J. Freedland
- Division of Urology, Department of Surgery and the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Section of Urology, Durham VA Medical Center, Durham, NC, USA
| | - Sophia George
- Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA
| | | | | |
Collapse
|
9
|
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande AJ, Li XN, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nat Neurosci 2021; 25:127. [PMID: 34907396 DOI: 10.1038/s41593-021-00994-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Alexandra Garancher
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Hiromichi Suzuki
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Svasti Haricharan
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Lianne Q Chau
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Meher Beigi Masihi
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Jessica M Rusert
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Paula S Norris
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Florent Carrette
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Megan M Romero
- Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Sorana A Morrissy
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.,Dept. of Biochemistry and Molecular Biology, Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
| | - Patryk Skowron
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Florence M G Cavalli
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Hamza Farooq
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Vijay Ramaswamy
- Division of Haematology/Oncology and Department of Paediatrics, Hospital for Sick Children, Toronto, Canada
| | - Steven J M Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Richard A Moore
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Andrew J Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Yussanne Ma
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Nina Thiessen
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Yisu Li
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Alaide Morcavallo
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Lin Qi
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.,Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Mari Kogiso
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Yuchen Du
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.,Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Patricia Baxter
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Jacob J Henderson
- Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA
| | - John R Crawford
- Departments of Pediatrics and Neurosciences, University of California, San Diego - Rady Children's Hospital, San Diego, CA, USA
| | - Michael L Levy
- Department of Neurosurgery, University of California San Diego - Rady Children's Hospital, San Diego, CA, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Yoon-Jae Cho
- Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA
| | - Aniruddha J Deshpande
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Xiao-Nan Li
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.,Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Louis Chesler
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Harald Wajant
- Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Oren J Becher
- Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Linda M Bradley
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Carl F Ware
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Michael D Taylor
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Robert J Wechsler-Reya
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
| |
Collapse
|
10
|
Abstract
The lethality of estrogen receptor alpha positive (ER+) breast cancer, which is often considered to have better prognosis than other subtypes, is defined by resistance to the standard of care endocrine treatment. Relapse and metastasis are inevitable in almost every patient whose cancer is resistant to endocrine treatment. Therefore, understanding the underlying causes of treatment resistance remains an important biological and clinical focus of research in this area. Growth factor receptor pathway activation, specifically HER2 activation, has been identified as 1 mechanism of endocrine treatment resistance across a range of experimental model systems. However, clinical trials conducted to test whether targeting HER2 benefits patients with endocrine treatment-resistant ER+ breast cancer have consistently and disappointingly shown mixed results. One reason for the failure of these clinical trials could be the complexity of crosstalk between ER, HER2, and other growth factor receptors and the fluidity of HER2 activation in these cells, which makes it challenging to identify stratifiers for this targeted intervention. In the absence of stratifiers that can be assayed at diagnosis to allow prospective tailoring of HER2 inhibition to the right patients, clinical trials will continue to disappoint. To understand stratifiers, it is important that the field invests in key understudied areas of research including characterization of the tumor secretome and receptor activation in response to endocrine treatment, and mapping the ER-HER2 growth factor network in the normal and developing mammary gland. Understanding these mechanisms further is critical to improving outcomes for the hard-to-treat endocrine treatment-resistant ER+ breast cancer cohort.
Collapse
Affiliation(s)
- Aloran Mazumder
- Aging and Cancer Immuno-oncology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
| | - Stephen Shiao
- Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Svasti Haricharan
- Aging and Cancer Immuno-oncology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
- Correspondence: Svasti Haricharan, PhD, Sanford Burnham Prebys, 10901 N Torrey Pines Rd, La Jolla, CA, USA.
| |
Collapse
|
11
|
Mazumder A, Jimenez A, Ellsworth R, Freedland S, George S, Bainbridge M, Haricharan S. Abstract 2521: Race specific differences in DNA damage repair dysregulation in breast cancer and association with outcome. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
African American (AA) estrogen receptor positive (ER+) breast cancer patients have worse outcomes than Caucasian Americans (CA) being 42 % more likely to die from the disease. However, AAs are severely underrepresented in currently available datasets of patient tumors, which precludes comprehensive approaches to identify race-specific molecular drivers of these poor outcomes. Endocrine therapy (ET) is the first line standard of care for ER+ breast cancer. Nevertheless, 1 in 4 patients develop ET resistance. Specific DNA damage/repair (DDR) defects have been shown to associate with poor outcome in CA patients, and to induce ET resistance. Whether these or other DDR defects contribute to poor outcomes observed in AA patients remains unknown. For the purpose of this investigation, we assessed the DDR dysregulation landscape of AA ER+ tumors using three independent tumor datasets (1) GSE78958 (2) GSE18229 (3) The Cancer Genome Atlas (TCGA) and two normal breast datasets (1) GSE43973 (2) GSE50939. This analysis identified a distinct set of AA ER+ tumors with simultaneous dysregulation of genes from multiple DDR pathways, rarely seen in CA tumors. This simultaneous dysregulation also associated with worse patient outcomes in all three datasets analyzed. This work constitutes the first systematic analysis of race-specific DDR dysregulation in ER+ breast cancer, and identifies DDR as a potential predictive biomarker for worse outcome seen in AA patients.
Citation Format: Aloran Mazumder, Athena Jimenez, Rachel Ellsworth, Stephen Freedland, Sophia George, Matthew Bainbridge, Svasti Haricharan. Race specific differences in DNA damage repair dysregulation in breast cancer and association with outcome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2521.
Collapse
Affiliation(s)
- Aloran Mazumder
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Athena Jimenez
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Rachel Ellsworth
- 2Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD
| | | | - Sophia George
- 4Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL
| | | | | |
Collapse
|
12
|
Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S. Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nat Commun 2021; 12:2940. [PMID: 34011995 PMCID: PMC8134423 DOI: 10.1038/s41467-021-23271-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 04/22/2021] [Indexed: 01/02/2023] Open
Abstract
Resistance to endocrine treatment occurs in ~30% of ER+ breast cancer patients resulting in ~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER inhibitors in ER+/HER2- patients have disappointed, likely due to a lack of predictive biomarkers. Here we demonstrate that loss of mismatch repair activates HER2 after endocrine treatment in ER+/HER2- breast cancer cells by protecting HER2 from protein trafficking. Additionally, HER2 activation is indispensable for endocrine treatment resistance in MutL- cells. Consequently, inhibiting HER2 restores sensitivity to endocrine treatment. Patient data from multiple clinical datasets supports an association between MutL loss, HER2 upregulation, and sensitivity to HER inhibitors in ER+/HER2- patients. These results provide strong rationale for MutL loss as a first-in-class predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2- breast cancer patients.
Collapse
MESH Headings
- Animals
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Cell Line, Tumor
- DNA Mismatch Repair/drug effects
- DNA Mismatch Repair/genetics
- Drug Resistance, Neoplasm/genetics
- Female
- Gene Knockdown Techniques
- Humans
- MCF-7 Cells
- Mice
- Mice, Nude
- Mice, SCID
- MutL Protein Homolog 1/genetics
- MutL Protein Homolog 1/metabolism
- MutL Proteins/genetics
- MutL Proteins/metabolism
- Proteins/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, ErbB-2/antagonists & inhibitors
- Receptor, ErbB-2/genetics
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Signal Transduction
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Nindo B Punturi
- Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Sinem Seker
- Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Vaishnavi Devarakonda
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Aloran Mazumder
- Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Rashi Kalra
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Ching Hui Chen
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Shunqiang Li
- Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA
| | - Tina Primeau
- Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA
| | - Matthew J Ellis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Shyam M Kavuri
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
| | - Svasti Haricharan
- Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
| |
Collapse
|
13
|
Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, Fusco N. Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell Int 2021; 21:266. [PMID: 34001143 PMCID: PMC8130151 DOI: 10.1186/s12935-021-01976-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 05/07/2021] [Indexed: 12/15/2022] Open
Abstract
The clinical outcome of patients with a diagnosis of hormone receptor (HR)+ breast cancer has improved remarkably since the arrival of endocrine therapy. Yet, resistance to standard treatments is a major clinical challenge for breast cancer specialists and a life-threatening condition for the patients. In breast cancer, mismatch repair (MMR) status assessment has been demonstrated to be clinically relevant not only in terms of screening for inherited conditions such as Lynch syndrome, but also for prognostication, selection for immunotherapy, and early identification of therapy resistance. Peculiar traits characterize the MMR biology in HR+ breast cancers compared to other cancer types. In these tumors, MMR genetic alterations are relatively rare, occurring in ~3 % of cases. On the other hand, modifications at the protein level can be observed also in the absence of gene alterations and vice versa. In HR+ breast cancers, the prognostic role of MMR deficiency has been confirmed by several studies, but its predictive value remains a matter of controversy. The characterization of MMR status in these patients is troubled by the lack of tumor-specific guidelines and/or companion diagnostic tests. For this reason, precise identification of MMR-deficient breast cancers can be problematic. A deeper understanding of the MMR biology and clinical actionability in HR+ breast cancer may light the path to effective tumor-specific diagnostic tools. For a precise MMR status profiling, the specific strengths and limitations of the available technologies should be taken into consideration. This article aims at providing a comprehensive overview of the current state of knowledge of MMR alterations in HR+ breast cancer. The available armamentarium for MMR testing in these tumors is also examined along with possible strategies for a tailored pathological characterization.
Collapse
Affiliation(s)
- Elham Sajjadi
- Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Konstantinos Venetis
- Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Roberto Piciotti
- Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Marco Invernizzi
- Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont, Viale Piazza D'Armi, 1, 28100, Novara, Italy
| | - Elena Guerini-Rocco
- Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Svasti Haricharan
- Department of Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, 92037, La Jolla, CA, USA
| | - Nicola Fusco
- Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
| |
Collapse
|
14
|
Haricharan S, Punturi N, Seker S, Devarakonda V, Kalra R, Chen CH, Mazumder A, Li S, Primeau T, Ellis M, Kavuri S. Abstract PD8-05: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-pd8-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogen receptor positive (ER+) breast cancer is a leading cause of cancer-related death globally. Resistance to standard of care endocrine treatment occurs in at least 30% of ER+ breast cancer patients resulting in ~40,000 deaths every year in the US alone. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance of ER+ breast cancer that is HER2- at diagnosis. However, clinical trials of pan-HER inhibitors in ER+/HER2- patients have disappointed, likely due to a lack of predictive biomarkers. Here we demonstrate that loss of MLH1, a principal mismatch repair gene, causally activates HER2 in ER+/HER2- breast cancer upon endocrine treatment. Additionally, we show that HER2 activation is indispensable for endocrine treatment resistant growth of MLH1-defective cells in vitro and in vivo. Consequently, inhibiting HER2 restores sensitivity to endocrine treatment in multiple experimental models including patient-derived xenograft tumors. Patient data from multiple clinical datasets (TCGA, METABRIC, Alliance (Z1031) and E-GEOD-28826) supports an association between MLH1 loss, HER2 upregulation, and sensitivity to trastuzumab in endocrine treatment-resistant ER+/HER2- patients. These results provide strong evidence that MLH1 could serve as a first-in-class predictive marker of sensitivity to combinatorial treatment with endocrine drugs and HER2 inhibitors in endocrine treatment-resistant ER+/HER2- breast cancer patients. Implications of this study extend beyond breast cancer to Lynch Syndrome cancers.
Citation Format: Svasti Haricharan, Nindo Punturi, Sinem Seker, Vaishnavi Devarakonda, Rashi Kalra, Ching-Hui Chen, Aloran Mazumder, Shungqiang Li, Tina Primeau, Matthew Ellis, Shyam Kavuri. Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD8-05.
Collapse
Affiliation(s)
| | - Nindo Punturi
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Sinem Seker
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | | | | | | | - Aloran Mazumder
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | | | - Tina Primeau
- 4Washington University in St Louis, St Louis, MO
| | | | | |
Collapse
|
15
|
Mazumder A, Jimenez A, Haricharan S. Abstract PO-090: Coordinate dysregulation of base excision repair and homologous recombination pathways predominates in ER+/HER2- breast tumors from African American patients, and associates with worse disease-specific outcomes. Cancer Epidemiol Biomarkers Prev 2020. [DOI: 10.1158/1538-7755.disp20-po-090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
African American (AA) women with breast cancer are 42 % more likely to die from the disease compared to their white counterparts. This is evident from population- based studies which show a disparity in breast cancer mortality rates within United States even when confounding factors related to socioeconomic status and lifestyle are considered. Most of these studies focus on triple negative breast cancer, however the majority of breast cancer patients are diagnosed with estrogen receptor positive (ER+) disease. This results in a gap in knowledge in understanding molecular factors that contribute to worse outcome in AA patients with ER+ breast cancer.
Endocrine therapy in the form of tamoxifen or aromatase inhibitor is first line standard of care for ER+ breast cancer. Nevertheless, 1 in 4 patients develop resistance to this treatment modality resulting in disease recurrence, metastasis and eventually death from disease. Recently, dysregulation of mismatch, nucleotide and base excision repair pathways were identified as causal to endocrine resistance and poor survival in Caucasian American ER+ breast cancer patients. Whether these same pathways, or distinct ones, associate with poor outcome in AA patients remains as yet unstudied. Here, we use a discovery data set with 87 AA patients and two publicly available validation data sets (TCGA and GSE50939 which has 49 and 45 AA patients respectively) to address this gap in knowledge. We demonstrate that a distinct subset of single stand break repair genes belonging to base excision repair (BER) and nucleotide excision repair (NER) pathways are downregulated specifically in tumors from AA patients. In parallel, double stand break repair genes from homologous recombination (HR) and Fanconi anemia (FA) pathways are upregulated in tumors from AA patients. Uniquely, tumors from AA patients more frequently have coordinated dysregulation of both homologous recombination and base excision repair genes, and this coordinate dysregulation associate with poor outcomes in AA patients. Overall, the results of this study provide the first thorough interrogation of DNA damage repair dysregulation in ER+/HER2- breast tumors from AA women. This systematic analysis identifies a unique profile of DNA repair dysregulation in AA patients and associates them with survival outcome. Datasets with better representation of AA patients are required for a more nuanced understanding of how DNA repair, and other molecular pathways, contribute to the worse outcomes seen in this underserved population. These results have implications for refining biomarker profiles by race, and improving precision medicine approaches.
Citation Format: Aloran Mazumder, Athena Jimenez, Svasti Haricharan. Coordinate dysregulation of base excision repair and homologous recombination pathways predominates in ER+/HER2- breast tumors from African American patients, and associates with worse disease-specific outcomes [abstract]. In: Proceedings of the AACR Virtual Conference: Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2020 Oct 2-4. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(12 Suppl):Abstract nr PO-090.
Collapse
Affiliation(s)
- Aloran Mazumder
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Athena Jimenez
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | | |
Collapse
|
16
|
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FM, Farooq H, Ramaswamy V, Morcavallo A, Henderson JJ, Olson JM, Cho YJ, Li XN, Chesler L, Marra MA, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. Abstract IA11: Overcoming immune evasion in pediatric brain tumors. Cancer Res 2020. [DOI: 10.1158/1538-7445.pedca19-ia11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Many immunotherapies act by enhancing T-cell killing of tumor cells. Cytotoxic T cells recognize antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. Our studies suggest that medulloblastomas and high-grade gliomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase Erap1, which are required for MHC-I trafficking to the cell surface. Treatment with tumor necrosis factor or lymphotoxin beta receptor agonist rescues expression of Erap1, Tap1, and MHC-I on p53 mutant tumor cells. In vivo, TNF treatment prolongs survival and markedly augments the efficacy of the immune checkpoint inhibitor anti-PD-1. These studies identify p53 as a key regulator of immune evasion in vivo and suggest that TNF could be used to enhance sensitivity of p53-mutant tumors to immunotherapy.
Citation Format: Alexandra Garancher, Hiromichi Suzuki, Svasti Haricharan, Meher B. Masihi, Jessica M. Rusert, Paula S. Norris, Florent Carrette, Megan M. Romero, Sorana A. Morrissy, Patryk Skowron, Florence M.G. Cavalli, Hamza Farooq, Vijay Ramaswamy, Alaide Morcavallo, Jacob J. Henderson, James M. Olson, Yoon-Jae Cho, Xiao-Nan Li, Louis Chesler, Marco A. Marra, Oren J. Becher, Linda M. Bradley, Carl F. Ware, Michael D. Taylor, Robert J. Wechsler-Reya. Overcoming immune evasion in pediatric brain tumors [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr IA11.
Collapse
Affiliation(s)
| | | | | | - Meher B. Masihi
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA,
| | | | - Paula S. Norris
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA,
| | - Florent Carrette
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA,
| | | | | | | | | | - Hamza Farooq
- 2Hospital for Sick Children, Toronto, ON, Canada,
| | | | | | | | | | - Yoon-Jae Cho
- 5Oregon Health & Science University, Portland, OR,
| | | | - Louis Chesler
- 4The Institute of Cancer Research, London, United Kingdom,
| | | | | | - Linda M. Bradley
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA,
| | - Carl F. Ware
- 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA,
| | | | | |
Collapse
|
17
|
Venetis K, Sajjadi E, Haricharan S, Fusco N. Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. Transl Cancer Res 2020; 9:4060-4064. [PMID: 35117775 PMCID: PMC8798497 DOI: 10.21037/tcr-20-1852] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Accepted: 05/07/2020] [Indexed: 11/06/2022]
Affiliation(s)
- Konstantinos Venetis
- Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy
- Phd Program in Translational Medicine, University of Milan, Milan, Italy
| | - Elham Sajjadi
- Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy
| | - Svasti Haricharan
- Department of Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Nicola Fusco
- Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
18
|
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande AJ, Li XN, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nat Neurosci 2020; 23:842-853. [PMID: 32424282 PMCID: PMC7456619 DOI: 10.1038/s41593-020-0628-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Accepted: 03/20/2020] [Indexed: 12/18/2022]
Abstract
Many immunotherapies act by enhancing the ability of cytotoxic T cells to kill tumor cells. Killing depends on T cell recognition of antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. In this study, we showed that medulloblastomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase Erap1, which are required for MHC-I trafficking to the cell surface. In vitro, tumor necrosis factor (TNF) or lymphotoxin-β receptor agonist can rescue expression of Erap1, Tap1 and MHC-I on p53-mutant tumor cells. In vivo, low doses of TNF prolong survival and synergize with immune checkpoint inhibitors to promote tumor rejection. These studies identified p53 as a key regulator of immune evasion and suggest that TNF could be used to enhance sensitivity of tumors to immunotherapy.
Collapse
Affiliation(s)
- Alexandra Garancher
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Hiromichi Suzuki
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Svasti Haricharan
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Lianne Q Chau
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Meher Beigi Masihi
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Jessica M Rusert
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Paula S Norris
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Florent Carrette
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Megan M Romero
- Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Sorana A Morrissy
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
- Dept. of Biochemistry and Molecular Biology, Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
| | - Patryk Skowron
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Florence M G Cavalli
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Hamza Farooq
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Vijay Ramaswamy
- Division of Haematology/Oncology and Department of Paediatrics, Hospital for Sick Children, Toronto, Canada
| | - Steven J M Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Richard A Moore
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Andrew J Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Yussanne Ma
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Nina Thiessen
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Yisu Li
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Alaide Morcavallo
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Lin Qi
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Mari Kogiso
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Yuchen Du
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Patricia Baxter
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Jacob J Henderson
- Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA
| | - John R Crawford
- Departments of Pediatrics and Neurosciences, University of California, San Diego - Rady Children's Hospital, San Diego, CA, USA
| | - Michael L Levy
- Department of Neurosurgery, University of California San Diego - Rady Children's Hospital, San Diego, CA, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Yoon-Jae Cho
- Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA
| | - Aniruddha J Deshpande
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Xiao-Nan Li
- Brain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Program of Precision Medicine PDOX Modeling of Pediatric Tumors, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Louis Chesler
- Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - Harald Wajant
- Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Oren J Becher
- Department of Pediatrics, Northwestern University, Chicago, IL, USA
| | - Linda M Bradley
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Carl F Ware
- Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Michael D Taylor
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
| | - Robert J Wechsler-Reya
- Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
| |
Collapse
|
19
|
Khanal S, Jimenez A, Haricharan S. Abstract P6-04-08: Mismatch repair defects induce metastasis of ER+ breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-04-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogen receptor (ER) positive breast cancer is a leading cause of cancer-related death among women globally. Metastasis and endocrine treatment resistance are the two principal causes of death from ER+ breast cancer. There are few available targeted therapeutics for metastatic, endocrine treatment resistant disease other than CDK4/6 inhibitors. However, CDK4/6 inhibitors only work in a subset of patients and markers that can identify these patients have not yet been discovered. Considering cost and toxicity associated with chronic use of these inhibitors, it is critical to identify (a) biomarkers of response (b) combinatorial approaches to enhance efficacy. To achieve these goals, we need to understand the biology underlying endocrine treatment resistance and CDK4/6 inhibitor response. We recently identified loss of the MutL complex of mismatch repair (MLH1 and PMS2), as a cause of endocrine treatment resistance in 5-10% of women with primary (non-metastasized) ER+ breast cancer. We also demonstrated that primary ER+ breast cancer cells defective in these genes lacked ATM/Chk2 activation and were, therefore, sensitized to CDK4/6 inhibitors.
Here, we present data demonstrating that MutL loss induces metastasis of ER+ breast cancer cells, which can be prevented/treated using ATM/Chk2 activators in combination with CDK4/6 inhibitors. We observed increased migration and invasion in three independent cell line models of MutL loss when treated with endocrine therapies in vitro, and increased lung colonization in vivo. We observe a similar phenotype in a PDX model of MutL defective ER+ disease. We also demonstrate significant inhibition of metastatic phenotypes upon administration of a combination of CDK4/6 inhibitors and ATM/Chk2 activators.
Alternative targeted therapies that are effective against metastatic ER+ breast cancer remain elusive, and lethality associated with this diagnosis remains high. Current standard care comprises of endocrine treatment administered with CDK4/6 inhibitors. Even when effective, this combination is costly and associated with side effects as it requires chronic administration to maintain stable disease. The results of this study suggest that (a) MutL loss can be a predictor of increased risk for metastatic disease (b) MutL defective ER+ breast cancer has increased sensitivity to CDK4/6 inhibitors (c) combinatorial use of ATM/Chk2 activators with CDK4/6 inhibitors could significantly benefit ER+ breast cancer patients with defective MutL. These potential outcomes could greatly improve quality of life and decrease cancer-related death in thousands of women every year.
Citation Format: Sujita Khanal, Athena Jimenez, Svasti Haricharan. Mismatch repair defects induce metastasis of ER+ breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-04-08.
Collapse
Affiliation(s)
- Sujita Khanal
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Athena Jimenez
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | | |
Collapse
|
20
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 2020; 24:1434-1444.e7. [PMID: 30089255 PMCID: PMC6171747 DOI: 10.1016/j.celrep.2018.07.009] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 05/08/2018] [Accepted: 07/01/2018] [Indexed: 01/29/2023] Open
Abstract
RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor-positive (ER+) breast cancer, but their role in disease pathogenesis remains unclear. We examined multiple ESR1 fusions and found that two, both identified in advanced endocrine treatment-resistant disease, encoded stable and functional fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, ESR1 exons 1-6 were fused in frame to C-terminal sequences from the partner gene. Functional properties include estrogen-independent growth, constitutive expression of ER target genes, and anti-estrogen resistance. Both fusions activate a metastasis-associated transcriptional program, induce cellular motility, and promote the development of lung metastasis. ESR1-e6>YAP1- and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, and a patient-derived xenograft (PDX) naturally expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression, explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.
Collapse
Affiliation(s)
- Jonathan T Lei
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Interdepartmental Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jieya Shao
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Jin Zhang
- Cancer Biology Division, Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA; Institute for Informatics (I(2)), Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Michael Iglesia
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Doug W Chan
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jin Cao
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Meenakshi Anurag
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Purba Singh
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Xiaping He
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Yoshimasa Kosaka
- Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan
| | - Ryoichi Matsunuma
- First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Robert Crowder
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Jeremy Hoog
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Chanpheng Phommaly
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Rodrigo Goncalves
- Department of Obstetrics and Gynecology, University of São Paulo School of Medicine (FMUSP), Cerqueira César, São Paulo 01246-903, Brazil
| | - Susana Ramalho
- Department of Obstetrics and Gynecology, Faculty of Medical Science, State University of Campinas - UNICAMP, Campinas, São Paulo 13083-970, Brazil
| | - Raquel Mary Rodrigues Peres
- Department of Obstetrics and Gynecology, Faculty of Medical Science, State University of Campinas - UNICAMP, Campinas, São Paulo 13083-970, Brazil
| | - Nindo Punturi
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Cheryl Schmidt
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Alex Bartram
- Queens' College, University of Cambridge, Cambridge CB3 9ET, UK
| | - Eric Jou
- Queens' College, University of Cambridge, Cambridge CB3 9ET, UK
| | - Vaishnavi Devarakonda
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Kimberly R Holloway
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - W Victoria Lai
- Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Oliver Hampton
- Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Anna Rogers
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Ethan Tobias
- University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Poojan A Parikh
- School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
| | - Sherri R Davies
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Shunqiang Li
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Cynthia X Ma
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Vera J Suman
- Alliance Statistical Center, Mayo Clinic, Rochester, MN 55905, USA
| | - Kelly K Hunt
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Mark A Watson
- Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Katherine A Hoadley
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
| | - E Aubrey Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 32224, USA
| | - Xi Chen
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Shyam M Kavuri
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Chad J Creighton
- Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
| | - Christopher A Maher
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA; The McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA
| | - Charles M Perou
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Svasti Haricharan
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Matthew J Ellis
- Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Interdepartmental Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
| |
Collapse
|
21
|
Anurag M, Haricharan S, Ellis MJ. CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? Clin Cancer Res 2019; 26:3-5. [PMID: 31690650 DOI: 10.1158/1078-0432.ccr-19-3119] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 10/17/2019] [Accepted: 11/01/2019] [Indexed: 11/16/2022]
Abstract
CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor-positive breast cancer. However, the identification of predictive markers that optimize their use is proving harder than expected. In this commentary we advocate for unbiased discovery and a collaborative approach across trials.See related article by Finn et al., p. 110.
Collapse
Affiliation(s)
- Meenakshi Anurag
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
| | - Svasti Haricharan
- Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys, La Jolla, California
| | - Matthew J Ellis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
| |
Collapse
|
22
|
Wechsler-Reya R, Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FM, Farooq H, Ramaswamy V, Jones SJ, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande A, Li XN, Chesler L, Marra MA, Becher OJ, Bradley LM, Ware CF, Taylor MD. TNF superfamily cytokines overcome immune evasion in medulloblastoma. The Journal of Immunology 2019. [DOI: 10.4049/jimmunol.202.supp.194.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Many immunotherapies act by enhancing T cell killing of tumor cells. CD8+ cytotoxic T cells recognize antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. Here we show that medulloblastomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase Erap1, which are required for MHC-I trafficking to the cell surface. Treatment with tumor necrosis factor (TNF) or lymphotoxin beta receptor agonist (LTβRag) rescues expression of Erap1, Tap1 and MHC-I on p53-mutant tumor cells. In vivo, TNF treatment prolongs survival and markedly augments the efficacy of the immune checkpoint inhibitor anti-PD-1. These studies identify p53 as a key regulator of immune evasion in vivo, and suggest that TNF could be used to enhance sensitivity of p53-mutant tumors to immunotherapy.
Collapse
Affiliation(s)
- Robert Wechsler-Reya
- 1Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Alexandra Garancher
- 1Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Hiromichi Suzuki
- 2Division of Neurosurgery, Hospital For Sick Children, Toronto, Canada
| | - Svasti Haricharan
- 3Lester & Sue Smith Breast Center, Department of Medicine, Baylor College of Medicine
| | - Meher Beigi Masihi
- 1Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Jessica M. Rusert
- 1Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Paula S. Norris
- 4Immunity and Pathogenesis Program, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Florent Carrette
- 4Immunity and Pathogenesis Program, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute
| | | | - Sorana A. Morrissy
- 6Developmental and Stem Cell Biology Program, Hospital For Sick Children, Toronto, Canada
| | - Patryk Skowron
- 6Developmental and Stem Cell Biology Program, Hospital For Sick Children, Toronto, Canada
| | - Florence M.G. Cavalli
- 7Program in Developmental and Stem Cell Biology, Hospital For Sick Children, Toronto, Canada
| | - Hamza Farooq
- 6Developmental and Stem Cell Biology Program, Hospital For Sick Children, Toronto, Canada
| | - Vijay Ramaswamy
- 8Division of Haematology/Oncology and Division of Paediatrics, Hospital For Sick Children, Toronto, Canada
| | - Steven J.M. Jones
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Richard A. Moore
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Andrew J. Mungall
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Yussanne Ma
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Nina Thiessen
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Yisu Li
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | - Alaide Morcavallo
- 10Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Lin Qi
- 11Preclinical Neuro-Oncology Research Program, Texas Children’s Cancer Center, Texas Children’s Hospital, Baylor College of Medicine
| | - Jacob J. Henderson
- 12Papé Family Pediatric Research Institute, Department of Pediatrics, Knight Cancer Institute, Oregon Health & Science University
| | - John R. Crawford
- 13Departments of Pediatrics and Neurosciences, University of California, San Diego, Rady Children’s Hospital San Diego
| | - Michael L. Levy
- 14Department of Neurosurgery, University of California, San Diego, Rady Children’s Hospital San Diego
| | - James M. Olson
- 15Clinical Research Division, Fred Hutchinson Cancer Research Center
| | - Yoon-Jae Cho
- 12Papé Family Pediatric Research Institute, Department of Pediatrics, Knight Cancer Institute, Oregon Health & Science University
| | - Ani Deshpande
- 1Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Xiao-Nan Li
- 11Preclinical Neuro-Oncology Research Program, Texas Children’s Cancer Center, Texas Children’s Hospital, Baylor College of Medicine
| | - Louis Chesler
- 10Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom
| | - Marco A. Marra
- 9Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
| | | | - Linda M. Bradley
- 4Immunity and Pathogenesis Program, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Carl F. Ware
- 4Immunity and Pathogenesis Program, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute
| | - Michael D. Taylor
- 2Division of Neurosurgery, Hospital For Sick Children, Toronto, Canada
| |
Collapse
|
23
|
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, M.G. Cavalli F, Farooq H, Ramaswamy V, J.M. Jones S, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande A, Li XN, Chesler L, Marra MA, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | | | | | | | - Jessica M Rusert
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Paula S Norris
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Florent Carrette
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | - Yisu Li
- BC Cancer Agency, Vancouver, BC, Canada
| | | | - Lin Qi
- Baylor College of Medicine, Houston, TX, USA
| | | | - John R Crawford
- University of California San Diego – Rady Children’s Hospital, San Diego, CA, USA
| | - Michael L Levy
- University of California San Diego – Rady Children’s Hospital, San Diego, CA, USA
| | - James M Olson
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Yoon-Jae Cho
- Oregon Health & Science University, Portland, OR, USA
| | - Ani Deshpande
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Xiao-Nan Li
- Baylor College of Medicine, Houston, TX, USA
| | - Louis Chesler
- The Institute of Cancer Research, London, United Kingdom
| | | | | | - Linda M Bradley
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Carl F Ware
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | | | | |
Collapse
|
24
|
Lei JT, Gou X, Seker S, Haricharan S, Lee AV, Robinson DR, Ellis MJ. Abstract P5-04-01: Functional and therapeutic significance of ESR1 fusions in metastatic ER+ breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Next-generation sequencing methods have identified several ESR1 fusion genes in treatment refractory ER+ breast cancer, however detailed functional studies in experimental models are lacking and how they might be targeted remains poorly understood. We recently reported two transcriptionally active, in-frame ESR1 fusions, ESR1-YAP1 and ESR1-PCDH11X, identified in a small cohort of metastatic ER+ cases, that induce not only pan-endocrine therapy resistance but also metastatic disease progression (Lei et al., Cell Reports, in press). Limited characterization of ESR1-DAB2 and ESR1-GYG1, also identified in metastatic ER+ disease from a recent study, suggests these two ESR1 fusions also drive estrogen-independent gene activation (Hartmaier et al., Annals of Oncology, 2018). Here, we functionally characterize ESR1-DAB2 and ESR1-GYG1 along with additional ESR1 fusions discovered in metastatic ER+ breast tumors to further support a causal role for in-frame ESR1 fusions in driving endocrine therapy resistance and promoting metastasis-associated biology, and explore therapeutic vulnerabilities induced by ESR1 fusion gene formation.
Methods. RNA-seq identified ESR1 fusions from treatment refractory, ER+ metastatic breast tumors. In-frame ESR1 fusions constructs were generated and stably expressed in ER+ breast cancer cell lines: T47D, MCF7, and ZR75-1. Estrogen-independent and fulvestrant-resistant growth was monitored in hormone-deprived stable cell lines. mRNA-qPCR was performed to examine expression of estrogen responsive and epithelial-to-mesenchymal transition (EMT) genes. In vitro sensitivity to CDK4/6 inhibition was tested with palbociclib and abemaciclib.
Results. In addition to previously described ESR1-YAP1, ESR1-PCDH11X, ESR1-DAB2, and ESR1-GYG1, that follow a pattern retaining the first 6 exons of ESR1 (ESR1-e6) fused in-frame to C-terminal sequences provided by the partner gene, additional in-frame ESR1-e6 fusions, ESR1-PCMT1, ESR1-ARNT2, and ESR1-ARID1B, all identified in metastatic ER+ samples, were found to follow the same fusion pattern. ESR1-DAB2 and ESR1-GYG1 produced stable ESR1 fusion proteins in ER+ breast cancer cell lines. In T47D, these two fusions drove estrogen-independent and fulvestrant-resistant growth. In addition, T47D and ZR75-1 models revealed that ESR1-DAB2 drove estrogen-independent expression of estrogen responsive genes and also EMT genes, including SNAI1, suggesting this fusion, like ESR1-YAP1 and ESR1-PCDH11X, could also drive metastasis. Treatment with CDK4/6 inhibitors suppressed growth induced by ESR1-DAB2 and ESR1-GYG1.
Conclusion. The majority of in-frame ESR1 exon 6 fusions found in metastatic ER+ breast are transcriptionally active, drive endocrine therapy resistant proliferation, and induce an EMT-like transcriptional program. The ability to block ESR1 fusion induced growth with a CDK4/6 inhibitor is clinically significant as ESR1 fusion gene formation renders ER insensitive to all endocrine therapies that target the ligand binding domain. Furthermore, clinical diagnosis of an active ESR1 fusion could potentially stratify patients for CDK4/6 inhibitor treatment. This presentation is the most complete description of the role for ESR1 fusions in endocrine therapy resistance and metastasis described to date.
Citation Format: Lei JT, Gou X, Seker S, Haricharan S, Lee AV, Robinson DR, Ellis MJ. Functional and therapeutic significance of ESR1 fusions in metastatic ER+ breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-01.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - X Gou
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - S Seker
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - AV Lee
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - DR Robinson
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh; University of Michigan, Ann Arbor
| |
Collapse
|
25
|
Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clin Cancer Res 2018; 24:4887-4899. [PMID: 29793947 PMCID: PMC6822623 DOI: 10.1158/1078-0432.ccr-17-3702] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 04/30/2018] [Accepted: 05/18/2018] [Indexed: 12/20/2022]
Abstract
Purpose: This study was undertaken to conduct a comprehensive investigation of the role of DNA damage repair (DDR) defects in poor outcome ER+ disease.Experimental Design: Expression and mutational status of DDR genes in ER+ breast tumors were correlated with proliferative response in neoadjuvant aromatase inhibitor therapy trials (discovery dataset), with outcomes in METABRIC, TCGA, and Loi datasets (validation datasets), and in patient-derived xenografts. A causal relationship between candidate DDR genes and endocrine treatment response, and the underlying mechanism, was then tested in ER+ breast cancer cell lines.Results: Correlations between loss of expression of three genes: CETN2 (P < 0.001) and ERCC1 (P = 0.01) from the nucleotide excision repair (NER) and NEIL2 (P = 0.04) from the base excision repair (BER) pathways were associated with endocrine treatment resistance in discovery dataset, and subsequently validated in independent patient cohorts. Complementary mutation analysis supported associations between mutations in NER and BER genes and reduced endocrine treatment response. A causal role for CETN2, NEIL2, and ERCC1 loss in intrinsic endocrine resistance was experimentally validated in ER+ breast cancer cell lines, and in ER+ patient-derived xenograft models. Loss of CETN2, NEIL2, or ERCC1 induced endocrine treatment resistance by dysregulating G1-S transition, and therefore, increased sensitivity to CDK4/6 inhibitors. A combined DDR signature score was developed that predicted poor outcome in multiple patient cohorts.Conclusions: This report identifies DDR defects as a new class of endocrine treatment resistance drivers and indicates new avenues for predicting efficacy of CDK4/6 inhibition in the adjuvant treatment setting. Clin Cancer Res; 24(19); 4887-99. ©2018 AACR.
Collapse
Affiliation(s)
- Meenakshi Anurag
- Department of Medicine, Baylor College of Medicine, Houston, Texas
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
| | - Nindo Punturi
- Department of Medicine, Baylor College of Medicine, Houston, Texas
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
| | - Jeremy Hoog
- Siteman Cancer Center Breast Cancer Program, Washington University School of Medicine, St. Louis, Missouri
| | - Matthew N Bainbridge
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
- Rady Children's Institute for Genomic Medicine, San Diego, California
| | - Matthew J Ellis
- Department of Medicine, Baylor College of Medicine, Houston, Texas.
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
| | - Svasti Haricharan
- Department of Medicine, Baylor College of Medicine, Houston, Texas.
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
26
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Romalho S, Peres RM, Punturi N, Schmidt C, Bartram A, Jou E, Lai WV, Hampton O, Rogers A, Tobias E, Parikh P, Davies SR, Li S, Ma CX, Suman V, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. Abstract 5240: Functional and therapeutic significance of ESR1 gene fusions in breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
RNA sequencing detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found only two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C-terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6>YAP1 and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.
Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Raquel M. Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, W V. Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E A. Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis. Functional and therapeutic significance of ESR1 gene fusions in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5240.
Collapse
Affiliation(s)
| | - Jieya Shao
- 2Washington University in St. Louis, St. Louis, MO
| | - Jin Zhang
- 2Washington University in St. Louis, St. Louis, MO
| | | | | | - Jin Cao
- 1Baylor College of Medicine, Houston, TX
| | | | | | - Xiaping He
- 3University of North Carolina, Chapel Hill, NC
| | | | | | | | - Jeremy Hoog
- 2Washington University in St. Louis, St. Louis, MO
| | | | | | - Susana Romalho
- 5University of São Paulo School of Medicine, Sao Paulo, Brazil
| | | | | | | | - Alex Bartram
- 7University of Cambridge, Cambridge, United Kingdom
| | - Eric Jou
- 7University of Cambridge, Cambridge, United Kingdom
| | - W V. Lai
- 8Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Ethan Tobias
- 9University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | - Shunqiang Li
- 2Washington University in St. Louis, St. Louis, MO
| | | | | | | | | | | | | | - Xi Chen
- 1Baylor College of Medicine, Houston, TX
| | | | | | | | | | | | | |
Collapse
|
27
|
Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. Abstract 917: Defects in multiple DNA damage repair pathways render endocrine treatment resistance in ER+ breast cancer patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Endocrine therapy resistance results in the death of majority of women diagnosed with breast cancer in the USA every year. Although a few markers can predict endocrine treatment failure, comprehensive understanding of the underlying cause and early detection of resistant population remains biggest challenge in the field. Recently, deficient expression or mutation in MutL mismatch repair components was found to cause 20% of intrinsic resistance in primary ER+ HER2- breast cancers. The role of other DNA damage repair (DDR) defects in inducing endocrine resistance therefore requires exploration. To address this question, a systematic study of associations between DDR dysregulation at DNA and RNA level and response to endocrine therapy was conducted using aggregated data from patient tumors from several neoadjuvant aromatase inhibitor (NeoAI) clinical trials. METABRIC, TCGA and Loi et al. datasets were used as validation datasets. Statistically significant correlations between endocrine therapy resistance and mutations in two single strand break repair (SSBR) pathways, i.e. nucleotide excision repair (NER; p=0.04) and base excision repair (BER; p=0.03), and one double strand break repair (DSBR) pathway, i.e. non-homologous end joining (NHEJ; p=0.004) were identified. A second set of analyses identified loss of expression of three genes: CETN2 and ERCC1 from the NER pathway and NEIL2 from BER as specifically associating with poor outcome despite endocrine treatment, emphasizing potential connections between NER and BER defects and endocrine treatment response. The functional role of CETN2, NEIL2 and ERCC1 loss in inducing intrinsic endocrine therapy resistance was experimentally validated in two breast cancer cell lines, and in ER+ PDX models. Finally, a DDR signature score was devised from baseline expression levels of candidate genes and was able to predict endocrine treatment failure in >30% of patients.In conclusion, this study describes a screening strategy for identifying novel predictive markers of endocrine therapy resistance in primary patient tumors. Three DDR pathways, NER, BER and NHEJ, were identified in clinical data as associating with endocrine resistance and validated using experimental model systems. Results reveal an understudied but impactful role for DDR pathways that may explain up to half of all endocrine therapy failure and open new avenues for early screening, predictive diagnostics and personalized medicine.
Citation Format: Meenakshi Anurag, Nindo Punturi, Jeremy Hoog, Matthew N. Bainbridge, Matthew J. Ellis, Svasti Haricharan. Defects in multiple DNA damage repair pathways render endocrine treatment resistance in ER+ breast cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 917.
Collapse
Affiliation(s)
| | | | - Jeremy Hoog
- 2Washington University School of Medicine, Houston, TX
| | | | | | | |
Collapse
|
28
|
Chang EC, Zheng Z, Philip L, Burcu C, Lei J, Singh P, Anurag M, Chan D, Li JD, Du XP, Shafaee MN, Banks K, Sacker S, Song W, Nguyen T, Cao J, Chen X, Haricharan S, Kavuri M, Kim BJ, Zhang B, Gutmann DH, Lanman RB, Foulds C, Ellis M. Abstract GS2-02: Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs2-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Inactivating germline mutations in the NF1 gene (encoding neurofibromin) cause neurofibromatosis type 1. In addition to peripheral nervous system tumors, NF1 patients are at higher risk for other cancers, including breast cancer. Tumor exome-sequencing studies demonstrate that approximately 20% of all human cancers have somatic NF1 mutations. NF1 has been best known for its ability to inactivate Ras as a GAP (GTPase Activating Protein). However, this function is served by a small GAP domain in a very large protein. Recurrent missense mutations inactivating the GAP activity are infrequent. In contrast, it is common to detect frameshift (FS) and nonsense (NS) NF1 mutations, which can create an NF1-null state deleting not only GAP, but also, potentially, undefined NF1 functions whose loss could also drive tumorigenesis.
As we reported at SABCS previously, in 600+ patients treated by tamoxifen adjuvant monotherapy, we found that FS/NS NF1 mutations independently correlate with relapse risk (HR=2.6, p=0.03). To explore this finding, we silenced NF1 in preclinical models of ER+ breast cancer, which markedly enhanced ER transcriptional activities, causing estradiol (E2) hypersensitivity and converted tamoxifen into an agonist (in vitro and in vivo). Most important, these activities depend on ER, but not on NF1's GAP activity. These findings readily explain the poor patient outcomes associated with NS/FS NF1 mutations, and reveal a previously unrecognized function for NF1 in ER regulation.
In the presence of an agonist, liganded ER repels co-repressors and recruits co-activators, while the reverse is true with an antagonist such as tamoxifen. Many co-regulators contain leucine/isoleucine rich motifs, which bind directly to the ligand-binding domain (LBD) in ER. NF1 has several of these motifs that are much more highly conserved in species with a functional ER pathway, and some of these are mutated in cancers (e.g., in our patient cohort). Furthermore, we found that NF1 canbind directly to ER, and that this binding is mediated between the ER LBD and the NF1 leucine-rich regions. Like a classic co-repressor, wildtype NF1 (but not mutants lacking GAP activity or the Leu-rich motif) binds to ER, and is recruited by ER to the ERE in the presence of tamoxifen, but not E2.
Further preclinical treatment studies indicate that while NF1-deficient ER+ breast cancer should not be treated by tamoxifen or AIs, fulvestrant remains effective. Furthermore, when fulvestrant is combined with dabrafinib and trametinib to inhibit Ras effectors Raf and MEK, apoptosis is induced in vitro, and tumor regression is observed in vivo. In conclusion, we have demonstrated that NF1 is a dual negative regulator at the intersection of two potent oncogenic signaling pathways, Ras and ER, and that NF1-deficient ER+ breast cancer patients may be more effectively treated by co-targeting the Ras and ER signaling. These patients, up to 10% of those with advanced ER+ breast cancer, can be readily identified for treatment by ctDNA analysis. A clinical trial is under development.
Citation Format: Chang EC, Zheng Z, Philip L, Burcu C, Lei J, Singh P, Anurag M, Chan D, Li JD, Du XP, Shafaee MN, Banks K, Sacker S, Song W, Nguyen T, Cao J, Chen X, Haricharan S, Kavuri M, Kim B-J, Zhang B, Gutmann DH, Lanman RB, Foulds C, Ellis M. Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS2-02.
Collapse
Affiliation(s)
- EC Chang
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - Z Zheng
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - L Philip
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - C Burcu
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - J Lei
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - P Singh
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - D Chan
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - JD Li
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - XP Du
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - MN Shafaee
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - K Banks
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - S Sacker
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - W Song
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - T Nguyen
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - J Cao
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - X Chen
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Kavuri
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - B-J Kim
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - B Zhang
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - DH Gutmann
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - RB Lanman
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - C Foulds
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| | - M Ellis
- Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St Louise, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China
| |
Collapse
|
29
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd8-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Dysregulation of the estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This study compares functional, transcriptional, and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) late stage (ESR1-YAP1 and ESR1-PCDH11x) breast cancers to gain a better understanding of therapeutic resistance and metastasis. Understanding the role of ESR1 fusions in inducing metastasis is critical, since the primary cause of death in breast cancer patients is through metastasis to distant sites.
Methods. RNA-seq screens identified ESR1 fusions from early and late stage, endocrine therapy resistant breast tumor samples. Functional experiments were conducted using ER+ breast cancer cell lines, xenograft, and PDX models to test the ability of ESR1 fusions to induce therapeutic resistance and metastasis. ChIP-seq and RNA-seq were performed to examine transcriptional properties and differential gene expression induced by the fusions which directed subsequent pharmacological experiments with a CDK4/6 inhibitor.
Results. ESR1-YAP1 and ESR1-PCDH11x promoted estrogen-independent and fulvestrant-resistant growth in vitro and induced greater tumor growth and increased metastatic capacity to the lungs of xenografted mice. In contrast, the ESR1-NOP2 fusion was sensitive to low estrogen conditions in vitro, and did not promote tumor growth. RNA-seq profiling revealed E2F targets pathway as the most highly enriched pathway induced by the ESR1 fusions. IHC revealed higher levels of pRb in ESR1-YAP1 and ESR1-PCDH11x xenograft tumors and subsequent CDK4/6 inhibition completely blocked tumor growth in an ESR1-YAP1 PDX model. Integrating RNA-seq with ChIP-seq data, we discovered a set of EMT and metastasis genes bound by all ESR1 fusions and WT-ER, but whose expression was strongly and uniquely up-regulated only by the ESR1-YAP1 and ESR1-PCDH11x fusions. These studies also revealed gained sites bound only by the ESR1-YAP1 and ESR1-PCDH11x fusions, not bound by WT-ER nor ESR1-NOP2. Genes mapping to these sites have a role in metastatic biology and were highly up-regulated by the YAP1 and PCDH11x fusions, potentially mediated by long range transcriptional activation.
Conclusion. ESR1-YAP1 and ESR1-PCDH11x are driver fusions that occur in drug-resistant, advanced stage breast cancer and are a new class of recurrent somatic mutation that can cause acquired endocrine therapy resistance, yet can be treated with CDK4/6 inhibition. These driver fusions also confer increased metastatic ability through their ability to drive expression of genes that contribute to EMT and metastasis. In contrast, ESR1-NOP2 did not produce functional protein and appears to be a passenger event. These studies may provide pre-clinical rationale for targeting ESR1 translocated breast tumors, since the presence of an ESR1 driver fusion places a patient in a therapeutic category where none of the currently available endocrine therapies are likely to be effective.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Singh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - SM Kavuri
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - RM Rodrigues-Peres
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
30
|
Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov 2017; 7:1168-1183. [PMID: 28801307 DOI: 10.1158/2159-8290.cd-16-1179] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 04/25/2017] [Accepted: 07/27/2017] [Indexed: 12/13/2022]
Abstract
Significant endocrine therapy-resistant tumor proliferation is present in ≥20% of estrogen receptor-positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismatch repair (MMR) complex (MLH1/3, PMS1/2), and demonstrate a direct role for MutL complex loss in resistance to all classes of endocrine therapy. We find that MutL deficiency in ER+ breast cancer abrogates CHK2-mediated inhibition of CDK4, a prerequisite for endocrine therapy responsiveness. Consequently, CDK4/6 inhibitors (CDK4/6i) remain effective in MutL-defective ER+ breast cancer cells. These observations are supported by data from a clinical trial where a CDK4/6i was found to strongly inhibit aromatase inhibitor-resistant proliferation of MutL-defective tumors. These data suggest that diagnostic markers of MutL deficiency could be used to direct adjuvant CDK4/6i to a population of patients with breast cancer who exhibit marked resistance to the current standard of care.Significance: MutL deficiency in a subset of ER+ primary tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy-resistant tumors. Therefore, markers of MutL dysregulation could guide CDK4/6 inhibitor use in the adjuvant setting, where the risk benefit ratio for untargeted therapeutic intervention is narrow. Cancer Discov; 7(10); 1168-83. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047.
Collapse
Affiliation(s)
- Svasti Haricharan
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Nindo Punturi
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Purba Singh
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Kimberly R Holloway
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Meenakshi Anurag
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Jacob Schmelz
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Cheryl Schmidt
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Jonathan T Lei
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas.,Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas
| | - Vera Suman
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota
| | - Kelly Hunt
- Department of Breast Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - John A Olson
- Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland
| | - Jeremy Hoog
- Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.,Siteman Cancer Center Breast Cancer Program, Washington University School of Medicine, Saint Louis, Missouri
| | - Shunqiang Li
- Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.,Siteman Cancer Center Breast Cancer Program, Washington University School of Medicine, Saint Louis, Missouri
| | - Shixia Huang
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.,Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
| | - Dean P Edwards
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.,Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.,Department of Immunology and Pathology, Baylor College of Medicine, Houston, Texas
| | - Shyam M Kavuri
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.,Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Matthew N Bainbridge
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.,Rady's Children's Hospital, San Diego, California
| | - Cynthia X Ma
- Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.,Siteman Cancer Center Breast Cancer Program, Washington University School of Medicine, Saint Louis, Missouri
| | - Matthew J Ellis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. .,Department of Medicine, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
31
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Matsunuma R, He X, Singh P, Kosaka Y, Crowder R, Haricharan S, Kavuri S, Hoog J, Phommaly C, Goncalves R, Romalho S, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou C, Creighton CJ, Maher C, Ellis MJ. Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulation of estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This current study compares functional and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) and advanced endocrine therapy resistant (ESR1-YAP1 and ESR1-PCDH11x) breast cancers. The YAP1 and PCDH11x fusions conferred estrogen-independent and fulvestrant-resistant growth in T47D, an ER+ breast cancer cell line in vitro and in vivo, in contrast to the NOP2 fusion which was sensitive to hormone deprivation. Immunohistochemical (IHC) staining of mouse lungs revealed significantly higher numbers of micrometastatic ER+ cells from the T47D tumors expressing the YAP1 and PCDH11x fusions than YFP control and NOP2 fusion. Estrogen response element (ERE) reporter and pull down assays revealed that although all ESR1 fusions studied bound EREs, only the YAP1 and PCDH11x caused ERE activation. Cell lines containing these “canonical” ESR1 fusions upregulated expression of ER responsive genes such as TFF1 and GREB1 in hormone deprived conditions. In contrast, the NOP2 fusion neither induced ERE activity nor upregulated TFF1 and GREB1 gene expression. The proliferative ability of canonical fusion-containing T47D cells was inhibited by palbociclib, a CDK4/6 inhibitor, in a dose-dependent manner. In vivo growth of patient-derived xenograft tumors naturally harboring the ESR1-YAP1 fusion (WHIM18) was significantly reduced in mice fed palbociclib-containing chow. Mice transplanted with WHIM18 also formed lung micrometastases, with an ER IHC staining pattern similar to lungs from YAP1 and PCDH11x fusion expressing T47D xenografts. In conclusion, in-frame ERE activating canonical fusions occur in end-stage, drug resistant, advanced breast cancer and can be added to ESR1 point mutations as a class of somatic mutation that may cause acquired resistance. Endocrine therapy resistant growth induced by these fusions can be treated with CDK4/6 inhibition, using an FDA approved drug, palbociclib, which could potentially improve outcomes in patients with ESR1 translocated tumors.
Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Ryoichi Matsunuma, Xiaping He, Purba Singh, Yoshimasa Kosaka, Robert Crowder, Svasti Haricharan, Shyam Kavuri, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Wei-Chu Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri Davies, Cynthia Ma, Vera Suman, Kelly Hunt, Mark Watson, Katherine A. Hoadley, Aubrey Thompson, Charles Perou, Chad J. Creighton, Chris Maher, Matthew J. Ellis. Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1033. doi:10.1158/1538-7445.AM2017-1033
Collapse
Affiliation(s)
| | - Jieya Shao
- 2Washington University School of Medicine in St. Louis, MO
| | - Jin Zhang
- 3Washington University in St. Louis, MO
| | | | | | | | - Xiaping He
- 4University of North Carolina Chapel Hill, NC
| | | | | | - Robert Crowder
- 2Washington University School of Medicine in St. Louis, MO
| | | | | | - Jeremy Hoog
- 2Washington University School of Medicine in St. Louis, MO
| | | | | | | | - Wei-Chu Lai
- 2Washington University School of Medicine in St. Louis, MO
| | | | - Anna Rogers
- 2Washington University School of Medicine in St. Louis, MO
| | - Ethan Tobias
- 2Washington University School of Medicine in St. Louis, MO
| | - Poojan Parikh
- 2Washington University School of Medicine in St. Louis, MO
| | - Sherri Davies
- 2Washington University School of Medicine in St. Louis, MO
| | - Cynthia Ma
- 2Washington University School of Medicine in St. Louis, MO
| | | | | | - Mark Watson
- 2Washington University School of Medicine in St. Louis, MO
| | | | | | | | | | | | | |
Collapse
|
32
|
Haricharan S, Ellis MJ. Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance? Oncoscience 2017; 4:77-78. [PMID: 28966940 PMCID: PMC5616200 DOI: 10.18632/oncoscience.363] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 09/20/2017] [Indexed: 11/25/2022] Open
Affiliation(s)
- Svasti Haricharan
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Matthew J Ellis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
| |
Collapse
|
33
|
Haricharan S, Schmelz J, Schmidt C, Singh P, Holloway KR, Anurag M, Li S, Kavuri SM, Huang S, Edwards DP, Suman V, Hunt K, Olson JA, Hoog J, Ma CX, Bainbridge MN, Ellis MJ. Abstract 489: Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogen receptor positive (ER+) breast cancer is treated with endocrine therapy but intrinsic resistance occurs in ~1/3 of patients and acquired resistance in ~1/5 of the remainder. While many resistance mechanisms have been explored, therapeutic strategies to overcome resistance in the clinical setting have seen mixed outcomes, and appear most effective in the acquired resistance setting. Understanding mechanisms of resistance and finding therapeutic strategies to target them, therefore, remain important challenges facing breast cancer researchers. In this study we systematically examine the role of DNA damage repair defects in inducing endocrine therapy resistance, a relatively understudied question of recent interest. We use in silico analysis of clinical datasets, in vitro experiments evaluating endocrine therapy resistance in response to DDR dysregulation in multiple breast cancer celllines, and in vivo validation using cellline xenograft and patient-derived xenograft models. We also use gene expression microarrays and RPPA data from cell lines, patient-derived xenografts and primary ER+ breast tumors to uncover therapeutic options that are validated in vitro and in vivo and corroborated by clinical trial data. The results of this study uncover an intriguing link between mismatch repair (MMR) deficiency, specifically of the MutL complex (MLH1/3, PMS1/2), and poor prognosis in ER+ disease. We find a direct role for MutL loss in endocrine therapy resistance in vitro and in vivo by knocking down multiple MutL genes using CRISPR and stable shRNA approaches validated using standard rescue experiments. We identify the underlying mechanism: MutL deficiency in ER+ breast cancer abrogates Chk2-mediated feedback inhibition of CDK4/6 that appears necessary for endocrine therapy responsiveness. Consequently, pharmacological targeting of CDK4/6 in vitro and in vivo significantly inhibits growth of endocrine therapy resistant MutL-deficient ER+ breast cancer cells. These results are corroborated by data from a neoadjuvant clinical trial demonstrating that cell cycle regulation of MutL-mutant tumors tends to be estrogen-independent but sensitive to CDK4/6 inhibitors. The results of this study provide important biological and clinically relevant insights. 1) MMR deficiency is unexpectedly causal to intrinsic endocrine therapy resistance 2) This causal effect appears to be mediated by abrogation of cell cycle checkpoint activation in response to endocrine therapy 3) MMR deficiency in a subset of ER+ tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy resistant tumors. While there are currently no biomarkers to guide the use of CDK4/6 inhibitors for ER+ breast cancer, markers of MMR dysregulation could identify patients in whom CDK4/6 inhibition should be used to prevent disease recurrence.
Citation Format: Svasti Haricharan, Jacob Schmelz, Cheryl Schmidt, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Shunqiang Li, Shyam M. Kavuri, Shixia Huang, Dean P. Edwards, Vera Suman, Kelly Hunt, John A. Olson, Jeremy Hoog, Cynthia X. Ma, Matthew N. Bainbridge, Matthew J. Ellis. Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 489. doi:10.1158/1538-7445.AM2017-489
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Kelly Hunt
- 4UT MD Anderson Cancer Center, Houston, TX
| | - John A. Olson
- 5University of Maryland, School of Medicine, Baltimore, MD
| | | | | | | | | |
Collapse
|
34
|
Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD2-03: Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. We previously reported an alternative ESR1 somatic gain-of-function chromosomal translocation event in a patient presenting with aggressive, endocrine therapy resistant estrogen receptor (ER) positive disease, producing an in-frame fusion gene consisting of N-terminal ESR1 and the C-terminus of the Hippo pathway coactivator YAP1 (ESR1-YAP1). We recently identified another ESR1 fusion through RNA sequencing (RNA-seq) in advanced stage ER+ disease from a chest wall recurrence in a male patient that was refractory to multiple lines of treatment. Two examples of fusions discovered in primary breast cancer samples include ESR1 fused in-frame to C-terminal sequences from NOP2 (ESR1-NOP2), identified in a resistant cohort from a RNA-seq screen focused on 81 primary breast cancers from aromatase inhibitor clinical trials, and a second ESR1 fusion, fused in-frame to the entire coding sequence of POLH (ESR1-POLH), that was identified from RNA-seq analysis of 728 Cancer Genome Atlas breast samples. This current study extends our previous characterization of ESR1-YAP1 by comparing functional and pharmacological properties of these three additional ESR1 gene fusion events of both early stage and advanced breast cancers.
Methods. In vitro and in vivo experiments were conducted to test ESR1 fusions to induce therapeutic resistance, and metastasis. The transcriptional and binding properties of each fusion was also examined. Pharmacological inhibition with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was utilized to assess drug sensitivity in ESR1 fusion containing breast cancer cells and in a patient derived xenograft (PDX) model expressing ESR1-YAP1 (WHIM18).
Results. The YAP1 and PCDH11x fusions conferred estrogen-independent and fulvestrant-resistant growth. Immunohistochemistry revealed significantly higher numbers of ER+ cells in lungs of mice xenografted with T47D cells expressing the YAP1 and PCDH11x fusions compared to YFP control, NOP2 and POLH fusions. Results from ChIP-seq and microarray studies suggest that these two fusions promote proliferation and metastasis through genomic action by binding estrogen response elements (ERE) and subsequent gene activation. We thereby define these fusions as “canonical” fusions compared to “non-canonical” NOP2 and POLH fusions, which demonstrated dramatically decreased genomic binding ability. The non-canonical fusions induced genes associated with basal-like breast cancer and promoted HER2, EGFR, and MAPK gene expression signatures in contrast to genes associated with cell cycle/proliferation induced by canonical fusions. The proliferative ability of canonical fusion-containing ER+ cells was inhibited by Palbociclib in a dose-dependent manner. In vivo WHIM18 tumors in mice fed with Palbociclib-containing chow demonstrated significantly reduced tumor volume, growth rate, and weight compared to tumors in mice on control chow.
Conclusions. In-frame ERE activating canonical fusions occur in end-stage drug resistant advanced breast cancer and can be added to ESR1 point mutations as a class of recurrent somatic mutation that may cause acquired resistance. Growth induced by these fusions can be antagonized by Palbociclib and is potentially clinically helpful.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD2-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X He
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X Chen
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
35
|
Cakar B, Chan D, Yan P, Zheng Z, Singh P, Lei JT, Haricharan S, Ellis M, Chang E. Abstract P1-08-07: Assessing the impact of loss of NF1 protein on endocrine therapy resistance. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The vast majority of breast cancers belong to the luminal subtype, which expresses the estrogen receptor-α (ER). Although great strides have been made in targeting the ER pathway for treating the ER+ tumors, relapse and death is common and ongoing. In order to identify the cause for treatment resistance, we have conducted a retrospective analyses on the tumor genomes of >600 patients treated by tamoxifen monotherapy in the adjuvant setting with a median follow-up of 10.4 years. Our data have revealed that NF1 (Neurofibromatosis type 1) gene loss of function mutations were greatly associated with poor prognosis. NF1 is a tumor suppressor acting mostly as a GAP (GTP ase activating protein) to switch off activated Ras. We aim to define the impact of loss of NF1 protein on patient outcome in ER+ breast cancer patients by establishing an immunohistochemistry (IHC) protocol to detect NF1.
Method and results: We have first surveyed commercially available antibodies by Western blot and found one that could efficiently detect endogenous NF1. We then use this to validate inducible shRNA clones against NF1, as well as a breast cancer cell line that is NF1-null. This antibody has high background. We have thus partially purified a commercially available NF1 antibody by preclearing using NF1-null cell lysate. We then performed immunostaining using NF1-silenced and null cells as control and found that NF1 is mostly cytoplasmic and nuclear. To get antibody of high quality, we have decided to make our own antibody by expressing a C-terminal fragment of NF1 as a GST-tagged protein (GST-NF1c). Production of polyclonal and monoclonal antibody is in progress.
Conclusion: Our clinical profiling data suggest that loss of NF1 protein, a very common event in a wide range of other cancers, promotes endocrine therapy resistance. An efficient IHC protocol will enable us to firmly validate whether loss of the NF1 protein indeed correlates with poor patient outcome. This method will ultimately enable us to identify high risk NF1 deficient patients and to properly treat them.
Citation Format: Cakar B, Chan D, Yan P, Zheng Z, Singh P, Lei JT, Haricharan S, Ellis M, Chang E. Assessing the impact of loss of NF1 protein on endocrine therapy resistance [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-08-07.
Collapse
Affiliation(s)
- B Cakar
- Baylor College of Medicine, Houston, TX
| | - D Chan
- Baylor College of Medicine, Houston, TX
| | - P Yan
- Baylor College of Medicine, Houston, TX
| | - Z Zheng
- Baylor College of Medicine, Houston, TX
| | - P Singh
- Baylor College of Medicine, Houston, TX
| | - JT Lei
- Baylor College of Medicine, Houston, TX
| | | | - M Ellis
- Baylor College of Medicine, Houston, TX
| | - E Chang
- Baylor College of Medicine, Houston, TX
| |
Collapse
|
36
|
Zheng ZY, Cakar B, Lavere P, Cao J, Yao J, Singh P, Lei JT, Toonen JA, Haricharan S, Anurag M, Shah K, Kavuri M, Chan DW, Chen X, Gutmann DH, Foulds CE, Ellis MJ, Chang EC. Abstract P1-08-01: Regulation of estrogen receptor-α by NF1. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Although great strides have been made in targeting the ER pathway for treating ER+ breast cancer, relapse and death is common and is closely linked to resistance to ER-targeting agents. As a result, the majority of deaths from breast cancer still come from ER+ tumors. To discover drivers for endocrine resistance, we have sequenced tumor DNAs from a cohort of >600 patients treated with 5-year tamoxifen (Tam) monotherapy with a median 10.4 years follow up. Our preliminary data show that the worst outcome mutations (Hazard Ratio of ∼3 for relapse) were mostly those of the Neurofibromatosis type 1 (NF1) gene (encoding Neurofibromin), with nonsense/frame shift mutations creating early stop codons.
Germline NF1mutations cause neurofibromatosis type 1, a common inherited disorder that predisposes individuals to both benign and malignant tumors of the nervous system, as well as an increased risk for breast cancer. Analysis of DNA sequencing data has also shown that the NF1 gene is mutated in a wide range of common cancers (e.g., melanoma, lymphoma, and cancers of the lung, breast, and colon). Thus, NF1-deficiency underlies the formation and/or progression of a large number of cancers, so that the development of therapies targeted to NF1-deficient malignancies would have broad impact.
These observations support the hypothesis that NF1 gene inactivation is associated with aggressive tumor behaviors, such as endocrine therapy resistance in breast cancer. The key focus of this study is to define how the NF1 protein neurofibromin, regulates endocrine therapy resistance. Although neurofibromin is best known as a negative regulator for Ras, our data show that it may have other functions.
Method. Our data suggest that many of the identified nonsense/frame shift create a NF1 null state; thus, we have used gene-silencing to recapitulate the effects of such NF1 mutations on the activities of ER+ breast cancer cells. NF1+ and NF1– ER+ breast cancer cells were grown in defined media to measure how estradiol (E2) and Tam impact their growth, transforming activities, and gene expression. The binding between neurofibromin and components of the ER transcriptional pathway was measured biochemically and using the mammalian two-hybrid system.
Results. Our data showed that NF1-silenced cells use Tam as an agonist and can grow with very little E2, and these activities are driven by enhanced recruitment of ER to the ERE, leading to efficient expression of many classic ER-responsive genes. Expressing the NF1-GAP domain does not restore normal responses to Tam and E2 in NF1-silenced cells, suggesting that neurofibromincan regulate ER activity in a Ras-independent manner. To investigate the possibility that neurofibromin can directly regulate ER, we found that it can bind ER; furthermore, neurofibromin was more strongly recruited to the ERE by Tam than by E2.
Conclusion. Our data support a model whereby neurofibromin acts like a co-repressor for ER. As such,NF1 loss may result in more aggressive tumor behaviors by activating, not only the Ras pathways, but also the ER transcriptional pathways. Simultaneous activation of two powerful oncogenic pathways by the loss of a single tumor suppressor may explain why neurofibromin is such a potent tumor suppressor lost in a wide range of cancers.
Citation Format: Zheng Z-Y, Cakar B, Lavere P, Cao J, Yao J, Singh P, Lei JT, Toonen JA, Haricharan S, Anurag M, Shah K, Kavuri M, Chan DW, Chen X, Gutmann DH, Foulds CE, Ellis MJ, Chang EC. Regulation of estrogen receptor-α by NF1 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-08-01.
Collapse
Affiliation(s)
- Z-Y Zheng
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - B Cakar
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - P Lavere
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - J Yao
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - P Singh
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - JT Lei
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - JA Toonen
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - K Shah
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - M Kavuri
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - X Chen
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - DH Gutmann
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - CE Foulds
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| | - EC Chang
- Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO
| |
Collapse
|
37
|
Abstract
In this issue of Cancer Cell, Sflomos et al. (2016) describe a robust preclinical animal model of ER⁺ breast cancer. The authors identify the critical role of the breast microenvironment in determining hormone response of ER⁺ breast cancer cells and in driving the luminal phenotype of breast cancer.
Collapse
Affiliation(s)
- Svasti Haricharan
- Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jonathan Lei
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA
| | - Matthew Ellis
- Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
| |
Collapse
|
38
|
Hein SM, Haricharan S, Johnston AN, Toneff MJ, Reddy JP, Dong J, Bu W, Li Y. Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress. Oncogene 2015; 35:1461-7. [PMID: 26096929 PMCID: PMC4688047 DOI: 10.1038/onc.2015.206] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Revised: 05/04/2015] [Accepted: 05/04/2015] [Indexed: 01/05/2023]
Abstract
In the normal mammary gland, the basal epithelium is known to be bipotent and can generate either basal or luminal cells, whereas the luminal epithelium has not been demonstrated to contribute to the basal compartment in an intact and normally developed mammary gland. It is not clear whether cellular heterogeneity within a breast tumor results from transformation of bipotent basal cells or from transformation and subsequent basal conversion of the more differentiated luminal cells. Here we used a retroviral vector to express an oncogene specifically in a small number of the mammary luminal epithelial cells and tested their potential to produce basal cells during tumorigenesis. This in-vivo lineage-tracing work demonstrates that luminal cells are capable of producing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling. These findings reveal the plasticity of the luminal compartment during tumorigenesis and provide an explanation for cellular heterogeneity within a cancer.
Collapse
Affiliation(s)
- S M Hein
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.,Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - S Haricharan
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - A N Johnston
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - M J Toneff
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - J P Reddy
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - J Dong
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.,Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - W Bu
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.,Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - Y Li
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.,Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
39
|
Haricharan S, Brown PH. Abstract P4-05-05: A novel TP53-dependent role for TLR4 in driving breast cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p4-05-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is a leading cause of cancer-related death. Toll-like receptor (TLR)-4 is an important mediator of cytokine secretion that is expressed in breast cancer cells, and is frequently mutated in a subset of breast tumors associated with high mutation load and poor patient survival. We show here that TLR4 plays an important role in driving breast cancer growth in a TP53 context-dependent manner. Using siRNA mediated knockdown, pharmacological inhibition and hyperactivation of TLR4 we demonstrate that TLR4 inhibits growth in breast cancer cells with wildtype TP53 by inducing G0/G1 arrest and decreasing mitotic entry. Conversely, in breast cancer cells with mutant TP53, TLR4 acts as an oncogene and drives cell growth by inducing mitosis. Furthermore, we identify the underlying mechanism for this dual TP53-dependent effect of TLR4 on breast cancer cell growth: differential interferon gamma (IFN-γ) secretion by tumor cells into their microenvironment. Hyperactivated TLR4 signaling in TP53 wildtype breast cancer cells results in increased IFN-γ secretion, identified by an unbiased cytokine array and validated by ELISA, thus inhibiting growth in an autocrine/paracrine fashion. Moreover, secreted IFN-γ is both necessary and sufficient for TLR4-induced growth inhibition in TP53 wildtype breast cancer cells. Finally, the dual TP53-dependent effect of TLR4 extrapolates to several other cancer types in silico, attaching potentially global significance to these results. Taken together, the data presented in this paper strongly suggest a novel role for TLR4 as a suppressor of cell growth in TP53 wildtype tumors, and identify differential IFN-γ secretion as the underlying mechanism. The results of this study are also translationally relevant, delineating the TP53 mutant breast cancer subset as a group that can benefit from pharmacological TLR4 inhibition. Most importantly, these results indicate a need for studying the effect of drivers of cancer growth pleiotropically rather than as isolated events.
Citation Format: Svasti Haricharan, Powel H Brown. A novel TP53-dependent role for TLR4 in driving breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-05-05.
Collapse
|
40
|
Haricharan S, Bainbridge MN, Scheet P, Brown PH. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 2014; 146:211-20. [PMID: 24839032 PMCID: PMC4061465 DOI: 10.1007/s10549-014-2991-x] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Accepted: 04/30/2014] [Indexed: 01/03/2023]
Abstract
Breast cancer is one of the most commonly diagnosed cancers in women. While there are several effective therapies for breast cancer and important single gene prognostic/predictive markers, more than 40,000 women die from this disease every year. The increasing availability of large-scale genomic datasets provides opportunities for identifying factors that influence breast cancer survival in smaller, well-defined subsets. The purpose of this study was to investigate the genomic landscape of various breast cancer subtypes and its potential associations with clinical outcomes. We used statistical analysis of sequence data generated by the Cancer Genome Atlas initiative including somatic mutation load (SML) analysis, Kaplan–Meier survival curves, gene mutational frequency, and mutational enrichment evaluation to study the genomic landscape of breast cancer. We show that ER+, but not ER−, tumors with high SML associate with poor overall survival (HR = 2.02). Further, these high mutation load tumors are enriched for coincident mutations in both DNA damage repair and ER signature genes. While it is known that somatic mutations in specific genes affect breast cancer survival, this study is the first to identify that SML may constitute an important global signature for a subset of ER+ tumors prone to high mortality. Moreover, although somatic mutations in individual DNA damage genes affect clinical outcome, our results indicate that coincident mutations in DNA damage response and signature ER genes may prove more informative for ER+ breast cancer survival. Next generation sequencing may prove an essential tool for identifying pathways underlying poor outcomes and for tailoring therapeutic strategies.
Collapse
Affiliation(s)
- Svasti Haricharan
- Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M.D. Anderson Cancer Center, P.O. Box 301439, Houston, TX, 77030-1439, USA,
| | | | | | | |
Collapse
|
41
|
Abstract
The mammary gland is a unique organ that undergoes extensive and profound changes during puberty, menstruation, pregnancy, lactation and involution. The changes that take place during puberty involve large-scale proliferation and invasion of the fat-pad. During pregnancy and lactation, the mammary cells are exposed to signaling pathways that inhibit apoptosis, induce proliferation and invoke terminal differentiation. Finally, during involution the mammary gland is exposed to milk stasis, programmed cell death and stromal reorganization to clear the differentiated milk-producing cells. Not surprisingly, the signaling pathways responsible for bringing about these changes in breast cells are often subverted during the process of tumorigenesis. The STAT family of proteins is involved in every stage of mammary gland development, and is also frequently implicated in breast tumorigenesis. While the roles of STAT3 and STAT5 during mammary gland development and tumorigenesis are well studied, others members, e.g. STAT1 and STAT6, have only recently been observed to play a role in mammary gland biology. Continued investigation into the STAT protein network in the mammary gland will likely yield new biomarkers and risk factors for breast cancer, and may also lead to novel prophylactic or therapeutic strategies against breast cancer.
Collapse
Affiliation(s)
- S Haricharan
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - Y Li
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
| |
Collapse
|
42
|
Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. eLife 2013; 2:e00996. [PMID: 24381245 PMCID: PMC3874103 DOI: 10.7554/elife.00996] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
While a first pregnancy before age 22 lowers breast cancer risk, a pregnancy after age 35 significantly increases life-long breast cancer risk. Pregnancy causes several changes to the normal breast that raise barriers to transformation, but how pregnancy can also increase cancer risk remains unclear. We show in mice that pregnancy has different effects on the few early lesions that have already developed in the otherwise normal breast—it causes apoptosis evasion and accelerated progression to cancer. The apoptosis evasion is due to the normally tightly controlled STAT5 signaling going astray—these precancerous cells activate STAT5 in response to pregnancy/lactation hormones and maintain STAT5 activation even during involution, thus preventing the apoptosis normally initiated by oncoprotein and involution. Short-term anti-STAT5 treatment of lactation-completed mice bearing early lesions eliminates the increased risk after a pregnancy. This chemoprevention strategy has important implications for preventing increased human breast cancer risk caused by pregnancy. DOI:http://dx.doi.org/10.7554/eLife.00996.001 Pregnancy changes the probability that a woman will later develop breast cancer. If a woman’s first pregnancy occurs before her 22nd birthday, the chances of developing breast cancer are reduced. However, if the first pregnancy occurs after her 35th birthday, there is an increased risk of breast cancer. It is not clear why this age-related difference exists, but as more women wait until their 30s to start a family, there is greater urgency to understand this difference. Breasts undergo extensive changes during pregnancy. This remodeling makes their cells less likely to multiply, and also less likely to develop tumors, which could explain the protective effect of pregnancy for younger women. But why would older women not reap the same benefits? One hypothesis is that older first-time mothers are more likely than younger first-time mothers to already have breast tissue with cells carrying cancer-causing mutations, or to have clusters of abnormal precancerous cells. Now, Haricharan et al. have tested this hypothesis by inserting two cancer-causing genes into female mice. Half of the mice were then made pregnant and allowed to nurse their young, whilst the other half were never mated. Although, both groups of mice later developed tumors, the mice that had been pregnant developed more tumors and did so faster. The increased cancer levels in the mice that had been pregnant were not due to them having more precancerous cells at the early stages of pregnancy than the unmated mice of the same age. Further, the precancerous cells in the impregnated mice did not proliferate faster than those in the mice that were never pregnant. Instead, pregnancy weakened the protective process that culls pre-existing precancerous cells. These cells evaded destruction by activating a signaling pathway called the STAT5 pathway in response to pregnancy hormones. Haricharan et al. also examined tissue samples from women with a very early form of breast cancer and found elevated levels of STAT5 in tumors from women who had been pregnant compared to those who had not been pregnant. The good news is that precancerous cells do not always become cancerous. However, for those women with a high risk of developing breast cancer, Haricharan et al. suggest that temporarily reducing STAT5 activity after pregnancy with medication might reduce this risk. Treating mice with anti-STAT5 drugs for a few weeks after they finished nursing their young lessened the elevated cancer risk, and so the next challenge is to see if this approach will also be effective in human clinical trials. DOI:http://dx.doi.org/10.7554/eLife.00996.002
Collapse
Affiliation(s)
- Svasti Haricharan
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Haricharan S, Hein SM, Dong J, Toneff MJ, Aina OH, Rao PH, Cardiff RD, Li Y. Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer. Oncogene 2013; 33:5729-39. [PMID: 24317513 PMCID: PMC4050040 DOI: 10.1038/onc.2013.521] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 10/17/2013] [Accepted: 10/23/2013] [Indexed: 12/15/2022]
Abstract
Pregnancy-associated breast cancers (PABCs) are tumors diagnosed during pregnancy or up to 5 years following parturition, and are usually high-grade, connective tissue-rich, and estrogen receptor (ER)/progesterone receptor-negative. Little is known about the cellular origin of PABCs or the mechanisms by which PABCs are initiated. Using the RCAS retrovirus to deliver the ErbB2 oncogene into the mammary epithelium of our previously reported MMTV-tva transgenic mice, we detected high-grade, poorly differentiated, stroma-rich and ER-negative tumors during pregnancy and lactation. These high-grade and stroma-rich tumors were less frequent in involuted mice or in age-matched nulliparous mice. More importantly, by generating a WAP-tva transgenic line for expression of ErbB2 selectively in WAP(+) mammary alveolar cells, we found that tumors had similar morphological phenotypes (high grade, poorly differentiated, stroma-rich and ER-negative), irrespective of the time since pregnancy and even in the absence of pregnancy. These data suggest that PABCs arise preferentially from an alveolar cell population that expands during pregnancy and lactation. This somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic strategies against PABC.
Collapse
Affiliation(s)
- S Haricharan
- Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - S M Hein
- Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - J Dong
- Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - M J Toneff
- Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - O H Aina
- Center for Comparative Medicine, University of California at Davis, Davis, CA, USA
| | - P H Rao
- Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA
| | - R D Cardiff
- Center for Comparative Medicine, University of California at Davis, Davis, CA, USA
| | - Y Li
- Lester & Sue Smith Breast Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
44
|
Lopez CR, Ribes-Zamora A, Indiviglio SM, Williams CL, Haricharan S, Bertuch AA. Ku must load directly onto the chromosome end in order to mediate its telomeric functions. PLoS Genet 2011; 7:e1002233. [PMID: 21852961 PMCID: PMC3154960 DOI: 10.1371/journal.pgen.1002233] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Accepted: 06/23/2011] [Indexed: 02/08/2023] Open
Abstract
The Ku heterodimer associates with the Saccharomyces cerevisiae telomere, where it impacts several aspects of telomere structure and function. Although Ku avidly binds DNA ends via a preformed channel, its ability to associate with telomeres via this mechanism could be challenged by factors known to bind directly to the chromosome terminus. This has led to uncertainty as to whether Ku itself binds directly to telomeric ends and whether end association is crucial for Ku's telomeric functions. To address these questions, we constructed DNA end binding-defective Ku heterodimers by altering amino acid residues in Ku70 and Ku80 that were predicted to contact DNA. These mutants continued to associate with their known telomere-related partners, such as Sir4, a factor required for telomeric silencing, and TLC1, the RNA component of telomerase. Despite these interactions, we found that the Ku mutants had markedly reduced association with telomeric chromatin and null-like deficiencies for telomere end protection, length regulation, and silencing functions. In contrast to Ku null strains, the DNA end binding defective Ku mutants resulted in increased, rather than markedly decreased, imprecise end-joining proficiency at an induced double-strand break. This result further supports that it was the specific loss of Ku's telomere end binding that resulted in telomeric defects rather than global loss of Ku's functions. The extensive telomere defects observed in these mutants lead us to propose that Ku is an integral component of the terminal telomeric cap, where it promotes a specific architecture that is central to telomere function and maintenance.
Collapse
Affiliation(s)
- Christopher R Lopez
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America.
| | | | | | | | | | | |
Collapse
|
45
|
Reddy JP, Peddibhotla S, Bu W, Zhao J, Haricharan S, Du YCN, Podyspanina K, Rosen JM, Donehower LA, Li Y. Abstract B21: Defining the DNA damage response-mediated barrier to ErbB2-induced transformation of somatic mammary cells in vivo. Cancer Res 2009. [DOI: 10.1158/0008-5472.fbcr09-b21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The DNA damage response (DDR) represents a signaling cascade, which is comprised of DNA damage sensors (such as γH2AX and 53BP1), ATM, Chk2, p53, among others, that becomes activated when confronted with DNA double strand breaks and other forms of DNA damage. The activation of the DDR, in addition to the ARF pathway, has recently been found to elicit apoptosis and senescence in response to oncogene activation. However, the significance of a DDR in blocking cancer progression has not been tested in breast carcinogenesis. Preneoplastic lesions in four germline transgenic models of breast cancer that express polyoma middle T antigen (PyMT), ErbB2, c-Myc, or H-Ras do not exhibit a DDR. We have previously reported a novel mouse model of mammary cancer, where oncogenes can be introduced into somatic mammary epithelial cells via retroviral infection of RCAS vectors into MMTV-tva mice (termed RCAS-TVA). Hyperplastic lesions in the mammary gland induced by somatic introduction of PyMT using the RCAS-TVA system display a robust DDR accompanied by increased p53 and apoptosis. This observation represents the first study, to our knowledge, to fully recapitulate DDR signaling in response to acute oncogenic stress in the in vivo mammary gland.
20–30% of all breast cancers display amplification of ErbB2, a cellular oncogene which, when activated in somatic murine mammary cells, forms sporadic tumors with a long latency. Like RCAS-PyMT, we found that p53 stabilization and apoptosis, as well as senescence, are induced by somatic activation of RCAS-ErbB2. In advanced RCAS-ErbB2-induced tumors, DDR signaling and ARF induction persist, yet p53 stabilization and apoptosis are lost. Surprisingly, attributes of senescence remain in some of the ErbB2 tumor cells. To demonstrate that the DDR is critical for oncogene-induced apoptosis and senescence, we generated RCAS-ErbB2 lesions in ATM-deficient mice. Strikingly, p53 stabilization, apoptosis, and senescence were no longer activated following ErbB2 activation in the absence of ATM signaling. These data suggest that a DDR plays a critical role in inhibiting breast carcinogenesis by inducing senescence and apoptosis, the latter, but not the former, of which is lost in progression to tumors. Furthermore, these findings indicate that therapies designed to bolster the activity of DDR signaling kinases and effectors may have a broad role in breast cancer prevention.
Citation Information: Cancer Res 2009;69(23 Suppl):B21.
Collapse
Affiliation(s)
| | | | - Wen Bu
- 1 Baylor College of Medicine, Houston, TX,
| | - Jing Zhao
- 1 Baylor College of Medicine, Houston, TX,
| | | | | | | | | | | | - Yi Li
- 1 Baylor College of Medicine, Houston, TX,
| |
Collapse
|
46
|
Liti G, Haricharan S, Cubillos FA, Tierney AL, Sharp S, Bertuch AA, Parts L, Bailes E, Louis EJ. Segregating YKU80 and TLC1 alleles underlying natural variation in telomere properties in wild yeast. PLoS Genet 2009; 5:e1000659. [PMID: 19763176 PMCID: PMC2734985 DOI: 10.1371/journal.pgen.1000659] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2009] [Accepted: 08/20/2009] [Indexed: 11/19/2022] Open
Abstract
In yeast, as in humans, telomere length varies among individuals and is controlled by multiple loci. In a quest to define the extent of variation in telomere length, we screened 112 wild-type Saccharomyces sensu stricto isolates. We found extensive telomere length variation in S. paradoxus isolates. This phenotype correlated with their geographic origin: European strains were observed to have extremely short telomeres (<150 bp), whereas American isolates had telomeres approximately three times as long (>400 bp). Insertions of a URA3 gene near telomeres allowed accurate analysis of individual telomere lengths and telomere position effect (TPE). Crossing the American and European strains resulted in F1 spores with a continuum of telomere lengths consistent with what would be predicted if many quantitative trait loci (QTLs) were involved in length maintenance. Variation in TPE is similarly quantitative but only weakly correlated with telomere length. Genotyping F1 segregants indicated several QTLs associated with telomere length and silencing variation. These QTLs include likely candidate genes but also map to regions where there are no known genes involved in telomeric properties. We detected transgressive segregation for both phenotypes. We validated by reciprocal hemizygosity that YKU80 and TLC1 are telomere-length QTLs in the two S. paradoxus subpopulations. Furthermore, we propose that sequence divergence within the Ku heterodimer generates negative epistasis within one of the allelic combinations (American-YKU70 and European-YKU80) resulting in very short telomeres. Telomere length is a complex trait that varies among individuals. Its regulation is critical to the process of aging, and altered length control can result in either senescence or immortalization. We detected extreme variation between different subpopulations of the wild yeast S. paradoxus, the closest relative to S. cerevisiae. By tagging individual telomeric ends in these two groups, we show that regardless of the total number of telomeric repeats, the critical length at which any telomere is replenished remains conserved. To detect the quantitative trait loci (QTLs) behind the length variation, we used the two sub-populations with the most polar distribution to generate progeny and perform linkage analysis. Further, we validated that naturally occurring sequence variations in YKU80 and TLC1, two genes previously shown to be important for telomere length maintenance, can explain part of the variation. We also identified other loci that influence both telomere length and gene silencing. Further investigation will provide more insights into the underlying genetic mechanism behind normal telomere regulation, potentially relevant in aging and aging-related disease such as cancer.
Collapse
Affiliation(s)
- Gianni Liti
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
- * E-mail: (GL); (EJL)
| | - Svasti Haricharan
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
- Baylor College of Medicine, Houston, Texas, United States of America
| | - Francisco A. Cubillos
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
| | - Anna L. Tierney
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
| | - Sarah Sharp
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
| | - Alison A. Bertuch
- Baylor College of Medicine, Houston, Texas, United States of America
| | - Leopold Parts
- The Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Elizabeth Bailes
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
| | - Edward J. Louis
- Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom
- * E-mail: (GL); (EJL)
| |
Collapse
|